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INTRODUCTION
Rectal cancer epidemiology
Worldwide, the incidence of colorectal cancer has increased in the last decade, especially in Western 
countries. This increase in incidence may be explained by modifiable lifestyle factors, such as 
smoking, alcohol intake, physical inactivity, obesity, low consumption of fruits and vegetables and high 
consumption of red meat and processed meat [1]. In addition, the introduction of population screening 
has contributed to an increased incidence. In the Netherlands, the incidence of colorectal cancer is one 
of the highest of all cancer types, with 15.306 new cases in 2016, of which 4461 were diagnosed as 
rectal cancer [2]. Since the early nineties, the incidence of rectal cancer has doubled and the 5-year 
survival has increased from 53% to 67% in recent years. 
Survival of rectal cancer patients is mainly dependent on the disease stage at the time of diagnosis, with a 
better prognosis for early diagnosed patients. Unfortunately, most patients are unaware of their disease 
until clinical symptoms occur, with an already advanced stage as a result. In order to improve survival for 
colorectal cancer patients, population screening was introduced in the Netherlands in 2014. This has 
led to an increased incidence, leading to more early stage colorectal cancer patients at diagnosis. Apart 
from possibly less aggressive treatment in some patients, improved overall survival of colorectal cancer 
patients has been anticipated [3].
Treatment
Surgery
Treatment advances in the last decades have led to improved local control and overall survival of 
rectal cancer patients. Surgery is the mainstay of treatment and a major step in surgical quality was 
made with the introduction of standardized total mesorectal excision (TME) surgery by Heald [4]. In a 
TME procedure, the entire mesorectal compartment is excised along anatomical planes. The specimen 
includes the rectum, surrounding mesorectum and perirectal lymph nodes, enclosed by the mesorectal 
fascia (MRF). The introduction of this standardized technique reduced local recurrence rates from over 
25% to approximately 10% [4–6].
Generally, two approaches of TME surgery are used. An abdominoperineal resection (APR) is generally 
used in patients with low lying tumors and involves removal of the anus, rectum and part of the sigmoid 
colon along with the complete mesorectum. Due to the removal of the anal sphincter complex, an APR 
always results in a permanent stoma. A low anterior resection (LAR) involves removal of the part of the 
rectum in which the tumor is located along with the surrounding mesorectum. An anastomosis is then 
performed to attach the colon to the remaining part of the rectum. To reduce the risk of anastomotic 
leakage, patients may have a temporary stoma, which can be reverted later on [7].
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For early stage rectal cancer patients with T1N0, an alternative to TME surgery might be a local excision. 
In this procedure, the tumor is locally excised through the anus using transanal endoscopic microsurgery 
(TEM), thereby saving the rectum and sphincter complex. Local excision surgery is associated with lower 
morbidity and mortality rates compared to TME surgery [8]. However, TEM has an increased risk of 
a non-radical resection [9] as well as a risk of leaving involved lymph nodes behind. As a result, local 
recurrence rates are substantially higher after TEM compared to TME [10].
(Chemo)radiotherapy
For more advanced cases, the addition of (chemo)radiotherapy to TME surgery further reduced local 
recurrence rates to 5-8% [11–14]. Two general treatment schedules are used as a neoadjuvant treatment. 
For intermediate risk patients, i.e. cT1-3N1 or cT3N0 with >5 mm extramural invasion and no involved 
mesorectal fascia (MRF), short-course radiotherapy (SC-RT) is given with 25 Gy in 5 fractions within 
one week in northern European countries.
The MRF is the resection plane of a TME resection and involvement of the MRF leads to positive 
circumferential resection margins (CRM) in a large number of patients. Several studies have demonstrated 
an increased local and distant recurrence risk after resections with a positive CRM [15]. If the distance of 
the primary tumor or involved lymph node to the MRF is smaller than or equal to 1 mm, it is considered an 
involved MRF and the patient is not eligible for direct TME surgery. For high risk patients, being cT4, cT3 
with involved MRF, and/or cN2 or extramesorectal pathological nodes, long-course chemoradiotherapy 
(LC-CRT) is given with 45-50 Gy in fractions of 1.8-2 Gy.
The addition of preoperative SC-RT in stage I-III patients has been investigated in the TME trial and the 
MRC CR07 trial. In the TME trial, patients with resectable rectal cancer were randomized between SC-
RT followed by immediate surgery or surgery alone [11]. In the MRC CR07 trial, patients with resectable 
rectal cancer were randomized between SC-RT with direct TME surgery or TME surgery with selective 
adjuvant chemoradiotherapy [14]. In both trials, a significant reduction in local recurrence rate was 
observed in patients with a negative CRM after TME in the radiotherapy group compared to the TME 
alone group. Because of the short interval between radiotherapy and TME surgery, no downstaging was 
observed [16].
The addition of chemotherapy to radiotherapy was investigated in the FFCD 9203 and EORTC 22921 
trials. In the EORTC 22921 trial, patients with resectable, T3-T4 rectal cancer were randomized between 
preoperative long-course radiotherapy with or without fluorouracil based chemotherapy. In addition, 
the role of adjuvant chemotherapy was investigated, resulting in a 2x2 design [12]. In the FFCD 9203 
trial, patients with resectable T3-4 rectal cancer were randomized between preoperative long-course 
radiotherapy with or without concomitant chemotherapy [17]. Time between (chemo)radiotherapy and 
surgery was 3-10 weeks. In both trials, the addition of chemotherapy resulted in lower local recurrence 
rates compared to long-course radiotherapy only. Ten year local recurrence was 22.4% vs 11.8% in the 
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EORTC 22921 trial and 5-year local recurrence was 16.5% vs 8.1% in the FFCD 9203 trial. In addition, 
more tumor downstaging was observed in the chemoradiotherapy group.
The Stockholm III trial investigated the optimal fractionation of neoadjuvant radiotherapy and timing 
to surgery by randomizing patients with resectable rectal cancer between short-course radiotherapy 
with immediate surgery, short-course radiotherapy with delayed surgery and chemoradiotherapy with 
delayed surgery. Interim analyses showed that patients in the SC-RT with delayed surgery group had a 
greater degree of tumor regression and a higher pathological complete response rate compared to the 
SC-RT with immediate surgery group [18,19]. After a follow-up of a minimum of 2 years, no differences 
in local recurrences, distal recurrences and overall survival were observed. In addition, the risk of surgical 
complications was lower in the delayed surgery groups. Preoperative toxicity was however higher.
Frail patients that are considered unfit for surgery are usually also unfit for chemotherapy. For these 
patients, definitive radiotherapy can be offered. Literature describes varying schedules and techniques, 
including external beam radiotherapy (EBRT), contact therapy and brachytherapy [20].
Toxicity and complications
The introduction of standardized TME surgery led to a substantial reduction in local recurrence rates. 
However, after TME surgery a permanent stoma is required in about 10-20% of cases and a temporary 
stoma is required in 60-70% of cases of which many are not reversed [21,22]. In addition, TME surgery 
can result in substantial morbidity, including bowel leaks (16%), urinary incontinence or retention (25-
34%), sexual dysfunction, and daily symptoms of urgency, incomplete emptying and stool frequency 
(30-40%) [23–27]. Thirty-days operative mortality is around 3-6% for patients <75 years of age and 
around 10-14% for patients >75 years of age [28].
While pre-operative (chemo)radiotherapy reduced local recurrence rates, it is also associated with an 
increased risk of side effects such as bowel and sexual dysfunction [29]. In the TME trial, 10-year local 
recurrence rates were lower in the radiotherapy group (5% vs 11%, p<0.0001), but no benefit in overall 
survival was observed (48% vs 49%). In a subgroup analysis, a benefit in overall survival was observed 
in the radiotherapy group in TNM stage III patients (50% vs 40%) with negative CRM. However, in TNM 
stage I and II patients, overall survival was lower in the radiotherapy group (65 vs 72% for stage I and 
51 vs 57% for stage II) [11]. Although one has to be careful with interpretation of unplanned subgroup 
analyses, these results seem to suggest that EBRT can cause a systemic effect. It has to be noted that 
patients in the TME trial were treated with a box technique with conventional 2D treatment planning, 
which may have contributed to the systemic effect. The results also show that patient selection based 
on disease stage could be useful, as overall survival was lower in stage I-II rectal cancer patients in the 
SC-RT group. In addition, reducing the integral dose and/or the dose to the organs at risk may reduce the 
side-effects associated with radiotherapy.
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Reducing treatment related toxicity and morbidity
Improvements in the treatment of rectal cancer patients have led to increased survival. As a result, long-
term outcome has become an increasingly important factor. In addition, the introduction of population 
screening will lead to earlier detection of the disease with probably improved survival as a result [3]. Both 
preoperative (chemo)radiotherapy and TME surgery are associated with toxicity and complications. As a 
result, research for rectal cancer treatment has focused on the reduction of radiation dose to (healthy) 
tissue and less extensive surgery or omission of surgery in selected patients.
Neoadjuvant radiotherapy
The target volume for neoadjuvant radiotherapy for rectal cancer typically encompasses the primary 
tumor, with elective irradiation of the whole mesorectum and presacral and internal iliac nodes, with the 
cranial border around the level of the sacral promontory and the caudal border at least 2 cm below the 
primary tumor. The most important organs at risk are the small bowel and the sphincter complex. Due to 
the large target volume and the proximity of these organs at risk to the target volume, dose is deposited 
in these organs at risk which causes part of the radiotherapy treatment related toxicity. In addition, dose 
deposition in nerves located in the pelvis may attribute to decreased functional outcome.
Reduction of dose to healthy tissue can be achieved by decreasing treatment margins, or by using an 
alternative treatment technique. Research on the interfraction displacement of the CTV resulted in 
guidelines on required margins for rectal cancer radiotherapy. These required margins reduced the PTV 
volumes on average with 16% (SC-RT) and 24% (LC-CRT) compared to previous standard practice [30]. 
EBRT is currently the standard treatment modality for neoadjuvant radiotherapy for rectal cancer. With 
EBRT, the patient is irradiated using an external beam, in which radiation dose is deposited in the healthy 
tissue surrounding the target volume before it reaches the target volume. An attractive alternative 
treatment technique is intracavitary irradiation, that offers the advantage of delivering a high dose to the 
tumor from the inside while sparing surrounding organs at risk due to a steep dose gradient. Intracavitary 
irradiation for rectal cancer is an experimental and specialized treatment technique that is not widely 
available. It can be applied using either contact therapy or brachytherapy. Contact therapy is performed 
using a 50 kV handheld tube under direct visual control of the tumor [31]. Due to the low energy and 
therefore a steep dose fall-off, a very localized treatment can be applied. Brachytherapy can be given 
endoluminally, with an applicator inserted in the rectum. A number of different rectal applicators are 
available, ranging from single channel rigid applicators to flexible multichannel applicators [32]. With 
an afterloading system, an irradiation source can be guided through the channels in order to irradiate 
the region of interest. The multichannel flexible applicator is often used for high-dose rate endorectal 
brachytherapy (HDREBT) and has the advantage that the eight channels are placed circumferential 
near the edge of the applicator, which allows conformal treatment planning by using the channels that 
are located near the tumor. Although HDREBT is an invasive procedure as opposed to EBRT, it is well 
tolerated by most patients [33].
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Compared to the target volume in neoadjuvant EBRT, brachytherapy reduces the irradiated volume 
considerably, leading to less dose to normal tissue. In addition, the dose in the tumor itself is significantly 
higher. However, potential positive lymph nodes that are further away from the tumor are not irradiated 
or receive a lower dose compared to EBRT. Nonetheless, the role of HDREBT as a neoadjuvant treatment 
was demonstrated by the group of Vuong et al. In a single center study, neoadjuvant HDREBT (4x 6.5 
Gy) was given for mainly T3 tumors (88.8%) with 34% of patients having N+. A final pathologic stage 
of T0N0-2 was reached in 27% and 5-year local control was 95% [34]. In a recent retrospective chart 
review that compared HDREBT to EBRT (mainly chemoradiotherapy), pathological complete response 
rates were similar (18.8% in the HDREBT group vs 17.1% in the EBRT group) and T-stage downstaging was 
significantly higher in the HDREBT group (59.4% vs 28.5%, p<0.01) [35]. Hesselager et al. performed 
a matched comparison of 318 patients treated with preoperative HDREBT (4x 6.5 Gy, TME after 4-8 
weeks), preoperative SC-RT (5x5 Gy, direct TME) and TME only [36]. Less perioperative bleeding was 
reported in the HDREBT group compared to the SC-RT and TME only group (380 mL, 947 mL and 919 
mL, respectively). In addition, less re-interventions were performed in the HDREBT group than in the 
SC-RT and TME only group (4.1%, 14.2% and 12.3%, respectively). Although it was not the primary 
endpoint of the study, a pathological complete response rate of 23.6% was reported after HDREBT. 
However, it is difficult to draw firm conclusions based on these non-randomized trials.
Organ preservation
The reported negative effects of rectal cancer surgery led to increased interest for organ preservation, 
in which surgery might be omitted if the patient experiences a complete response after neoadjuvant 
therapy. In these patients, a ‘watch and wait’ strategy with omission of surgery and a strict follow-up 
protocol seems to be a safe alternative to surgery [37]. Surgery and the related morbidy and mortality 
are then avoided. 
A pathological complete response (pCR) is observed in 15-25% of patients after standard 
chemoradiotherapy [38,39]. Complete response rates up to 50% are observed in centers with a 
dedicated watch and wait protocol, probably due to better patient selection [40,41]. Complete 
response rates might be increased by delivering a higher dose to the tumor [42,43]. This may therefore 
be beneficial in organ preservation strategies in order to increase the chance of a complete response. 
Tumor dose can be increased by applying a boost using EBRT or intracavitary irradiation.
A randomized trial comparing 13x3 Gy radiotherapy with or without an endocavitary boost using X-ray 
contact therapy (85 Gy in 3 fractions) reported an improved clinical complete response rate (24% vs 
2%) in the boost group [44]. No difference in local relapse and acute or postoperative toxicity were 
reported and 2-year overall survival was similar. Another randomized trial compared LC-CRT (28 x 1.8 
Gy) with- or without HDREBT boost (2 x 5 Gy) in resectable T3 and T4 rectal cancer patients [45]. 
The R0 resection rate was higher in the boost group (99% vs 90%) as was the major response rate 
defined as tumor regression grade 1 and 2 (44% vs 29%). No difference was found in toxicity or surgical 
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complications. Unfortunately, no difference in pCR rate was reported. The HERBERT trial was a dose 
escalation trial in which a HDREBT boost in 3 weekly fraction of 5-8 Gy was applied after 13 x 3 Gy EBRT 
in inoperable and elderly patients [46]. The maximum tolerated dose was determined at 7 Gy. Overall, a 
CR rate of 60% was observed. However, the treatment came with substantial risk of toxicity, with 40% 
grade ≥3 proctitis. 
In order to facilitate organ preservation in early stage rectal cancer patients, (chemo)radiotherapy has 
to be given in order to control the tumor. This group of patients would normally not receive neoadjuvant 
treatment as the standard of care for these patients is TME surgery. The risk of pelvic lymph node 
involvement or distal mesorectal nodal involvement is very low in early rectal cancer patients. Therefore, it 
is doubtful whether the typically used large target volumes are required for these patients and reduction 
of the target volume to only include the peritumoral region of the primary tumor and mesorectum 
seems reasonable. The significant volume reduction might lead to decreased treatment-related toxicity 
without compromising oncological outcome. This is currently being investigated in the STAR-TReC 
trial, which assesses the feasibility of short-course radiotherapy or long-course chemoradiotherapy 
with subsequent two-stage response assessment as an alternative to TME surgery. Patients with T1-
3bN0M0 rectal cancer are randomized between TME, organ preservation utilizing LC-CRT and organ 
preservation utilizing SC-RT. The radiotherapy target volume only includes the mesorectum [47].
Treatment delivery techniques
In order to deliver radiotherapy safely, a target volume needs to be defined to steer the treatment 
planning. In general, three target volumes are defined: the gross tumor volume (GTV), the clinical target 
volume (CTV) and the planning target volume (PTV). The GTV is defined as macroscopic tumor tissue 
which can be seen, palpated or imaged. The CTV is defined as the GTV plus the volume that is expected 
to contain any microscopic tumor deposits. Since microscopic tumor deposits in the tissue surrounding 
the tumor cannot be imaged, guidelines have been developed for delineation of the CTV for rectal cancer 
based on local recurrence patterns in the pelvis [48].
To ensure full coverage of the CTV by the prescribed dose, geometrical deviations of the treatment 
process should be taken into account. These deviations for example include CTV delineation errors, setup 
errors of the patient with respect to the treatment machine, and inter- and intrafraction CTV motion. 
Geometrical deviations are separated into two components: treatment preparation (systematic errors) 
and treatment execution (random errors). Systematic errors result in a shift of the dose distribution with 
respect to the target volume, while random errors result in blurring of the dose distribution [49]. The 
geometrical deviations are taken into account by adding a PTV margin to the CTV. Increasing the margin 
size will increase the chance that the CTV receives full coverage by the prescribed dose. However, with 
increasing margin size, more healthy tissue will be irradiated with risk of side-effects.
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Image-guided external beam radiotherapy
EBRT delivery techniques have evolved in the past decades to deliver radiation doses with increasing 
conformality. During the mid-nineties, a box technique was commonly used. It utilizes multiple (e.g. 
3 or 4) rectangular beams, aimed at the target at any angle in the transverse plane. Each beam was 
homogeneous in terms of intensity. This technique was replaced by 3D conformal radiotherapy. Using a 
multileaf collimator, the shape of each beam could be adapted to the shape of the PTV. A more conformal 
approach is intensity-modulated radiotherapy (IMRT), in which each beam is divided into segments. 
The beam intensity can be varied individually for each segment, resulting in more conformal treatment 
plans with a more homogeneous dose distribution within the PTV compared to the more conventional 
delivery techniques [50,51]. IMRT can also be delivered with a rotating gantry, in which rotation speed 
and beam intensity can be modulated, called volumetric arc therapy. Each improvement in radiotherapy 
delivery technique led to more conformal treatment plans, with higher dose gradients at the edges of the 
target volume. As a result, the treatment plans will be less forgiving in terms of geometrical deviations. 
Small deviations can lead to underdosage of the target volume if insufficient margins are used as the 
target volume will move out of the high dose region.
In image-guided radiotherapy (IGRT), corrections are applied based on measurements of the geometrical 
deviations. The imaging devices that are used to measure the geometrical deviations have evolved in the 
past years. In the nineties, an electronic portal imaging device (EPID) was used to acquire 2D projection 
images by measuring the exit dose [52]. The bony anatomy of the patient could be visualized and the 
position of the bony anatomy with respect to the treatment field could be corrected to match that of 
the treatment plan, if necessary.
New imaging modalities that could be used for setup correction were introduced in the last decade, 
including in-room CT, kV-CBCT on a linear accelerator and MV-CT on a helical radiotherapy unit. All 
these modalities have in common that they could perform three-dimensional (3D) imaging of the patient 
on the treatment table. However, the soft tissue contrast of these modalities is limited, which makes 
setup correction based on any other tissue than bony anatomy challenging [53]. In a GTV boost setting, 
setup correction can therefore not be performed on the GTV itself. As an alternative, fiducial markers 
could be used as a surrogate for the GTV. Fiducials have been used for setup correction of the target 
volume in prostate cancer and esophageal cancer [54,55]. The most recent advancement in onboard 
imaging is the MR-guided radiotherapy system [56]. With the superior soft tissue contrast of MRI, 
setup correction could be performed based on a direct visualization of the GTV. However, MR-guided 
radiotherapy systems are not widely available yet.
With increased interest for organ preservation and GTV dose escalation, improvements aimed at boost 
delivery for rectal cancer are timely. Although extensive research has been performed on the inter- and 
intrafraction displacement of the CTV relative to the bony anatomy, limited research was performed on 
the inter- and intrafraction displacement of the GTV relative to bony anatomy to determine margins for 
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a GTV boost [57–59]. As a result, a wide range of clinically used PTV margins of 7-30 mm is described 
in literature [60–64]. 
Setup correction could potentially be performed based on the fiducials instead of bony anatomy. To 
do so, the fiducials need to be representative of the GTV and the fiducials should be visible on MRI to 
accurately determine the fiducial-GTV spatial relationship. Literature on the use of fiducials in rectal 
cancer patients focuses on insertion technique, retention rate and complications [65,66]. The stability 
of fiducials with respect to the GTV has not been investigated. MRI visibility of fiducials has been 
evaluated in phantoms, but no in-vivo analysis has been reported [67,68].
Image-guided brachytherapy
The HDREBT procedure using the flexible multichannel applicator has been described first by Vuong 
et al. [69]. During endoscopy, the length and size of the tumor is assessed and endoluminal clips are 
attached to the rectal wall near the tumor to be able to visualize the tumor extent on radiographs for 
position verification. The target volume and endoluminal clips are delineated on a planning CT scan 
with applicator in situ and the applicator is reconstructed, which means that the position of the eight 
catheter channels in the applicator are denoted on the CT scan. Before irradiation, position verification 
of the applicator is performed. Dummy catheters containing tungsten markers that can be visualized 
on a radiograph are inserted into three channels of the applicator. Subsequently, anterior-posterior and 
lateral radiographs are acquired of the patient with applicator in situ. The position of the endoluminal 
clips and tungsten markers are used to check the insertion depth and rotation of the applicator. If the 
applicator is positioned correctly, irradiation is initiated.
Due to the steep dose gradient of HDREBT, interfractional anatomical variations of millimetres can 
have a substantial impact on dose to the target volume or organs at risk. Most publications on the 
use of HDREBT describe oncological outcomes, but do not report on the technical aspects of the 
brachytherapy procedure [70–72]. Initial publications describe a procedure using a single planning CT 
scan for all subsequent fractions [69,73]. More recent publications describe a more adaptive approach, 
acquiring a planning CT scan at each fraction [74,75]. So far, the possible dosimetric benefit of using an 
adaptive approach has not been reported.
HDREBT treatment planning is currently performed using a planning CT, on which accurate localization 
of the tumor is difficult due to limited soft tissue contrast. MRI could be used to accurately determine 
the tumor location due to its superior soft tissue contrast [76]. Given that the endoluminal clips that 
are used for position verification create large artifacts on MRI [77], alternative MRI-compatible fiducial 
markers may be used. However, similar to the potential application of fiducial markers in an EBRT boost, 
the visibility on MRI and the stability with respect to the GTV has not been investigated.
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A further improvement in the HDREBT procedure would be to omit the planning CT scan and perform 
delineation and treatment planning on MRI only. MRI-only brachytherapy is already the standard for 
brachytherapy of cervical cancer [78]. Reconstruction of the rigid applicator is performed by rigidly 
registering a model of the applicator to the applicator on the MRI scan. However, such an approach is 
not available for the flexible rectum applicator. In addition, the applicator causes a signal void on the 
currently used anatomical sequences and the individual channels cannot be identified. Therefore, the 
challenge in MRI-only HDREBT lies in the reconstruction of the flexible applicator on MRI.
Thesis outline
As described, both TME surgery and radiotherapy are associated with increased risk of side-effects. 
As a result, research is focused on increasing the dose to the tumor to achieve higher response rates 
for possible organ preservation and on the reduction of irradiated (healthy) tissue. The purpose of this 
thesis is to reduce uncertainties in image-guided radiotherapy of rectal cancer to increase the accuracy 
of external beam radiotherapy boosting and high-dose rate endorectal brachytherapy.
Initial publications on HDREBT for rectal cancer describe the use of a single planning CT for all 
subsequent fractions, while more recent literature describes a procedure using a planning CT at each 
fraction. However, a dosimetric comparison between the two approaches has not been performed to 
date. The question is whether the increased patient burden of a planning CT scan at each fraction is 
justified by any dosimetric improvement in terms of target volume coverage and dose to organs at risk. 
Chapter 2 describes the difference between the two approaches in terms of target volume coverage and 
dose to the organs at risk.
MRI-compatible fiducial markers can be used for HDREBT as an alternative to the endoluminal clips. 
This would allow the use of MRI for treatment planning for HDREBT. For EBRT, setup correction based 
on fiducial markers could potentially increase the accuracy of a GTV boost compared to setup correction 
on bony anatomy. To accomplish this, the fiducial markers need to be visible on MRI to determine the 
spatial relationship between fiducials markers and the GTV. Chapter 3 evaluates the MRI visibility of four 
different gold fiducial markers.
To enable MRI-only planning for HDREBT, the applicator and the individual channels need to be visible 
on MRI. However, the applicator creates a signal void on currently used anatomical MRI sequences. 
Chapter 4 investigates whether an ultrashort echo time sequence can be used to visualize the individual 
channels within the applicator and reports on the geometric fidelity.
To use fiducials as a surrogate for the GTV, the stability of the fiducials with respect to the GTV needs 
to be determined. In Chapter 5, the stability of implanted gold fiducial markers relative to the GTV is 
determined. Furthermore, the inter- and intrafraction displacement of the GTV is characterized and 
required margins for different setup correction scenarios in a EBRT GTV boost setting are suggested.
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In the STAR-TReC trial, a novel target volume is used which includes only the mesorectum. Mesorectum 
only planning is intended for early stage rectal cancer with the aim of reducing the CTV and thereby 
reducing dose to the healthy tissue while maintaining local control. Chapter 6 describes the results of a 
quality assurance program for mesorectum only planning.
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ABSTRACT
Purpose
In this planning study, we investigated the dosimetric benefit of repeat CT-based treatment planning 
at each fraction versus the use of a single CT-based treatment plan for all fractions for high-dose rate 
endorectal brachytherapy (HDREBT) for rectal cancer.
Methods and materials
We included eleven patients that received a CT scan with applicator in situ for all three fractions. 
The treatment plan of the first fraction was projected on the repeat CT scans to simulate the use of a 
single treatment plan. Additionally, replanning was performed on the repeat CT scans and these were 
compared to the corresponding projected treatment plans.
Results
Repeat CT-based treatment planning resulted on average in a 21% higher (p=0.01) conformity index 
compared to single CT-based treatment planning. Projecting the initial treatment plan to the repeat CT 
scans of fraction two and three, 12/22 fractions reached a CTV D98 of 85% of the prescribed dose of 7 
Gy, which increased to 14/22 using replanning. For the remaining fractions, median CTV D98 was 4.2 Gy 
and an intervention would be necessary to correct applicator balloon setup or to remove remaining air 
and/or feces between the CTV and the applicator.
Conclusions
Using a single CT-based treatment plan for all fractions may result in a suboptimal treatment at later 
fractions. Therefore, repeat CT imaging should be the minimal standard practice in HDREBT for rectal 
cancer to determine whether an intervention would be necessary. Replanning based on repeat CT 
imaging resulted in more conformal treatment plans and is therefore recommended.
INTRODUCTION
Total mesorectal excision is the mainstay in the treatment of rectal cancer. For more advanced cases, 
the addition of neoadjuvant (chemo)radiotherapy has resulted in lower local recurrence rates, but 
none of the recent trials has demonstrated a benefit in overall survival [1–4]. Unfortunately, (chemo)
radiotherapy is associated with an increased risk of side effects such as bowel and sexual dysfunction 
[5]. Vuong et al. introduced high-dose rate endorectal brachytherapy (HDREBT) as a replacement 
of neo-adjuvant external beam radiation therapy (EBRT) with promising results in local control [6,7]. 
For patients unfit or unwilling to undergo surgery, definitive or palliative radiotherapy are alternatives. 
Rijkmans et al. demonstrated the feasibility of a HDREBT boost after EBRT in inoperable patients [8]. 
Compared to EBRT, HDREBT can deliver high doses to the tumor while sparing surrounding organs due 
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to a steeper dose gradient [7]. As a consequence, HDREBT has the potential to decrease morbidity and 
reduce the risk of side effects [9]. However, the steeper dose gradient means that an anatomical inter-
fraction variation of millimeters can have a high impact on the delivered dose to the target volume or 
surrounding organs. Therefore, high precision is required in imaging, contouring and treatment planning.
For HDREBT treatment planning, the conventional approach is to use the treatment plan generated 
at the first fraction, for all later fractions [10,11]. Alternatively, an adaptive approach could be used by 
creating a new treatment plan based on new imaging acquired at each fraction, taking into account 
inter-fraction anatomical variation [12,13]. For cervical cancer, several studies on image-guided 
brachytherapy compared the use of one treatment plan for all fractions to an adaptive approach using 
a newly generated treatment plan at each fraction [14,15]. The treatment plan for the first fraction was 
simulated on the imaging of the later fractions. The results showed that the treatment plan based on 
imaging of the first fraction did not lead to comparable target volume coverage and dose to organs at 
risk at later fractions [14,15]. Nowadays, repeat MR imaging is therefore recommended in brachytherapy 
for cervical cancer [16].
Most studies on the use of HDREBT for rectal cancer focus on oncological outcome and treatment related 
toxicity in the pre-operative setting, with limited detail on treatment planning. They do not address 
the question of using a non-adaptive or adaptive approach [9,17–19]. Vuong et al. initially reported a 
non-adaptive approach using one planning CT scan with applicator in situ on which a treatment plan 
is generated and used for all later fractions [10,11]. Recent publications by the same group describe an 
adaptive approach generating a new treatment plan based on a new CT scan for each fraction [12,13]. A 
recent abstract concludes that an adaptive approach resulted in a more conformal dose distribution [20].
In our study, we further investigated the comparison between a non-adaptive and an adaptive approach 
and added a quantification of conformity. Additionally, we analyzed the repeat CT scans and reported 
causes of insufficient target volume coverage. The aim of this study was to determine the differences 
regarding treatment plan conformity, target volume coverage and dose to organs at risk between using a 




For the current study, we selected eleven patients from the HERBERT trial in whom repeat CT scans 
with applicator in situ were available at each fraction (the HERBERT trial, registered with the Dutch 
Central Committee on Research Involving Human Subjects; registration no. NL17037.031.07) [8,21].
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Treatment
All patients were treated with 13x3 Gy EBRT at four fractions per week, followed by three weekly 
fractions of HDREBT using a prescription dose of 5-8 Gy starting six weeks after conclusion of EBRT. 
We adapted the brachytherapy equipment, application and positioning procedures from Devic et al. as 
described in Rijkmans et al. [8,11]. Patients received an enema prior to the CT scan with applicator in situ 
at each fraction. 
We acquired a planning CT scan with applicator in situ prior to the first fraction. An inflatable balloon 
around the applicator on the opposite side of the clinical target volume (CTV) was used to fixate the 
applicator and to decrease the dose to the normal rectal wall. Treatment planning was performed using 
Oncentra Brachy (Elekta, Veenendaal, The Netherlands). The aim for treatment planning was to cover the 
CTV with the 100% isodose while containing the 400% isodose within the applicator. Repeat CT scans 
with applicator in situ were acquired for research purposes. In case of obvious differences compared to 
the CT scan of the first fraction, the treatment plan was adapted accordingly. These adapted treatment 
plans were not used in this study.
Delineation
The CTV was defined as residual macroscopic tumor and scarring after EBRT. CTV, anus, mesorectum 
and healthy rectal wall were delineated by two observers with help of diagnostic MRI, rectoscopy images 
and inserted endoluminal clips at the proximal and distal border of the tumor. The rectoscopy images 
were acquired before EBRT and before the first brachytherapy fraction. Comparing CTV delineations 
between fractions of the same patient was allowed to check for consistency. In case of discrepancy 
between delineations, consensus was sought.
Projection and replanning
To determine the differences in conformity, CTV coverage and dose to organs at risk between the use of 
a single treatment plan for all fractions and a new treatment plan at each fraction, the treatment plan of 
the first fraction and the new treatment plan were compared for each repeat CT scan. In order to obtain 
the dose distribution of the initial treatment plan on the repeat CT scans, the treatment plan of the 
first fraction was projected on the repeat CT scans. For this purpose, the most cranial activated dwell 
position was identified on the repeat CT scans in the same location with respect to the most cranial slice 
of the CTV delineation as on the CT scan of the first fraction. Subsequently, the dwell position pattern 
and dwell times were copied.
An experienced radiation treatment technologist created new treatment plans based on the repeat CT 
scans. As a result, for each repeat CT scan we thus obtained both a projected treatment plan of the first 
fraction and a new treatment plan.
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Analysis
To quantify dose conformity, the COnformal INdex (COIN) parameter was used, as defined by Baltas et 
al. in the following equation [22]:
With TVRI the tumor volume covered by the reference isodose, TV the tumor volume, VRI the reference 
isodose volume, NCO the number of critical organs, VCOref,i the volume of the critical organ with index i 
covered by the reference isodose and VCO,i the volume of the critical organ with index i (Figure 1). The 
healthy rectal wall, mesorectum and anus were considered critical organs. The COIN parameter ranges 
from 0-1, with 0 representing no conformity and 1 representing full conformity.
The HERBERT trial was a dose escalation study and patients were treated with a prescription dose of 
5-8 Gy [8]. Therefore, for reporting of dose parameters, we chose to scale the dose distributions to a 
prescription dose of 7 Gy. To quantify CTV coverage, the CTV D98 parameter (i.e. the minimal dose to
Figure 1. Schematic representation of the parameters of the COIN equation: tumor volume (TV, A + B), tumor volume 
covered by the 100% isodose (TV
RI 
, B), healthy rectal wall (V
CO 





 is the volume encompassed by the 100% reference isodose, represented by the dotted line. 
The three filled dots on the lower left side of the applicator represent activated dwell positions.
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98% of the CTV volume) was collected for each treatment plan. For the dose to organs at risk, the D2cc 
(i.e. the minimal dose to the 2 cc of the organ at risk that receives the highest dose) for mesorectum and 
anus were collected. Additionally, a point dose on the healthy rectal wall directly opposing the delineated 
CTV within the center slice of the CTV was chosen to quantify dose to the healthy rectal wall.
We visually analyzed all CT scans and if a suboptimal applicator balloon orientation or air and/or feces 
between the CTV and the applicator were observed, an intervention would be required to correct 
applicator balloon orientation or to remove air and/or feces.
Statistics
We used SPSS Statistics 23 (IBM Corp. Released 2015. IBM SPSS Statistics for Windows, Version 23.0. 
Armonk, NY: IBM Corp.) for statistical analysis. The Friedman test was used to test for volume differences 
of the CTV delineations between the three CT scans. A univariate analysis of variance was performed 
for each dependent variable (COIN, CTV D98, healthy rectal wall dose and D2cc of the mesorectum and 
anus). Included independent variables were plan type (projection or replanning), intervention required 
(yes or no), timepoint (fraction two or three) and patient (one through eleven). All tests were two-sided 
and the significance threshold was set at 0.05.
RESULTS
CTV delineation
The average delineated CTV volume for all CT scans was 6.8 cc (range 2.4–13.0). Delineated CTV 
volumes did not differ significantly between the three CT scans for each patient (p=0.31).
Initial treatment planning
Table 1 shows the results for COIN and CTV D98 for the treatment plan of the first fraction, all projections 
and all new treatment plans. Results are presented as median (range). The median COIN for treatment 
plans of the first fraction was 0.14 (0.04–0.20) and the median CTV D98 was 5.8 Gy (3.6–7.3). On four 
of the eleven CT scans, air and/or feces was seen between the CTV and the applicator. As a result of 
this, combined with the constraint of the 400% isodose within the applicator, the CTV coverage and 
conformity were lower in the corresponding four treatment plans (Figure 2). The median COIN and CTV 
D98 were 0.09 (0.04–0.13) and 5.6 Gy (3.6–5.8), respectively. An intervention would be necessary to 
remove air and/or feces before creating a more conformal treatment plan with higher CTV coverage. The 
median COIN and CTV D98 for the seven remaining treatment plans was 0.15 (0.13–0.20) and 6.3 Gy 
(4.6–7.3), respectively.
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Table 1. Conformity (COIN) and target volume coverage (CTV D98) for the initial treatment plan of the first CT scan 
and the projection and replanning for the repeat CT scans of all patients. Results are presented as median (range) 
unless indicated differently.
Parameter Initial treatment 
plan











Number of CT scans
 All 11 22 22
 Only interventions 4 8 8
 Excl. interventions 7 14 14
COIN (-)
 All 0.14 (0.04 – 0.20) 0.13 (0.01 – 0.18) 0.15 (0.02 – 0.19) 0.02 (-0.02 – 0.08) 0.01 1.21
 Only interventions 0.09 (0.04 – 0.13) 0.08 (0.01 – 0.15) 0.11 (0.02 – 0.16) 0.02 (-0.02 – 0.08) 0.17 1.31
 Excl. interventions 0.15 (0.13 – 0.20) 0.14 (0.07 – 0.18) 0.15 (0.11 – 0.19) 0.02 (-0.01 – 0.04) < 0.001 1.15
CTV D98 (Gy)
 All 5.8 (3.6 – 7.3) 6.4 (3.3 – 7.8) 6.6 (2.8 – 7.6) 0.3 (-1.0 – 2.4) 0.11 1.07
 Only interventions 5.6 (3.6 – 5.8) 4.2 (3.3 – 6.9) 5.0 (2.8 – 5.9) 0.1 (-1.0 – 1.7) 0.89 1.03
 Excl. interventions 6.3 (4.6 – 7.3) 6.9 (3.7 – 7.8) 7.0 (6.1 – 7.6) 0.5 (-0.8 – 2.4) 0.06 1.10
Projection
The treatment plan of the first fraction was projected on the repeat CT scans of the second and third 
fraction for each patient, resulting in 22 projections. The median COIN and CTV D98 of all projections 
were 0.13 (0.01–0.18) and 6.4 Gy (3.3–7.8), respectively. In some of the 22 repeat CT scans, air and/or 
feces was seen between the CTV and the applicator (5/22), a suboptimal orientation of the applicator 
balloon was observed (2/22) or the applicator balloon was not inflated (1/22). For the projections on 
these eight repeat CT scans (from six patients), the median COIN and CTV D98 were 0.08 (0.01–0.15) 
and 4.2 Gy (3.3–6.9), respectively. An intervention would be necessary to remove air and/or feces or to 
correct applicator balloon orientation before creating a more conformal treatment plan with higher CTV 
coverage. For the remaining 14 projections (from nine patients), the median COIN and CTV D98 were 
0.14 (0.07–0.18) and 6.9 Gy (3.7–7.8), respectively. Figure 3 shows an example of a patient in which the 
projections lead to similar conformity and CTV coverage as the initial treatment plan and a patient in 
which air and feces is seen on the CT scan of the third fraction leading to lower conformity and CTV 
coverage.
Replanning
New treatment plans were generated based on the repeat CT scans for each patient, resulting in 22 
new treatment plans. The median COIN and CTV D98 were 0.15 (0.02–0.19) and 6.6 Gy (2.8–7.6), 
respectively. 
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Figure 2. Example of a CT scan in which full coverage of the CTV was not possible considering the constraint of the 
400% isodose within the applicator. Air and feces are seen between the CTV and the applicator. The 400%, 100%, 
75% and 50% isodoses are shown.
For the new treatment plans based on the eight repeat CT scans that required an intervention, the median 
COIN and CTV D98 were 0.11 (0.02–0.16) and 5.0 Gy (2.8–5.9), respectively. For the remaining 14 new 
treatment plans, the median COIN and CTV D98 were 0.15 (0.11–0.19) and 7.0 Gy (6.1–7.6), respectively.
Projection versus replanning
There was a statistically significant effect of plan type (p=0.01) and intervention required (p=0.002) 
on the COIN parameter considering all cases. The COIN was on average 21% higher after replanning 
compared to the projected treatment plans. Considering the cases that did not require an intervention, 
COIN was on average 15% higher after replanning (Table 1).
There was a statistically significant effect of intervention required (p=0.001) on CTV D98, considering 
all cases. Only borderline significance was reached on the effect of plan type in the subgroup of cases 
that did not require an intervention (p=0.06). In those cases, CTV D98 was on average 10% higher 
after replanning. One case showed an increase of CTV D98 of 2.4 Gy (66%, from 3.7 Gy to 6.1 Gy) after 
replanning and another case showed an increase of CTV D98 of 1.7 Gy (42%, from 4.0 Gy to 5.7 Gy). In 
one case, replanning resulted in a CTV D98 decrease of 1.0 Gy (-15%, from 6.9 to 5.9 Gy). 
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Figure 3. An example of a patient in which the projections (B+C) lead to similar conformity and CTV coverage as the 
initial treatment plan (A), and a patient in which the projections lead to similar conformity and CTV coverage (E) and 
lower conformity and CTV coverage (F, due to air and feces) compared to the initial treatment plan (D). The 400%, 
100%, 75% and 50% isodoses are shown.
All other differences in CTV D98 were smaller than 1.0 Gy.
When considering a plan acceptable when the CTV D98 is at least 85% of the prescribed dose and 
at least 90% of the initial treatment plan at the first fraction, 12/22 projections were considered 
acceptable versus 14/22 new treatment plans. In the eight remaining unacceptable treatment plans, an 
intervention would have been necessary to achieve an acceptable treatment plan.
Dose to organs at risk
The dose to organs at risk is presented in Table 2. There was a statistically significant effect of intervention 
required on D2cc of the mesorectum considering all cases (p<0.001). No other significant effects were 
observed. In one case, after replanning, a reduction of the rectal wall point dose larger than 1 Gy (3.1 Gy) 
was observed. In another case, a decrease of mesorectum D2cc of more than 1 Gy (1.3 Gy) was observed. 
In another patient with a very distal tumor, an increase of the anus D2cc of 2.3 Gy and 2.1 Gy for fraction 
two and three was observed. All other differences in anus D2cc were smaller than 1 Gy.
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Table 2. Dose to organs at risk (rectal wall point dose and D2cc of mesorectum and anus) for the initial treatment plan 
of the first CT scan and the projection and replanning for the repeat CT scans of all patients. Results are presented as 
median (range) unless indicated differently.
Parameter Initial treatment 
plan










Number of CT scans
 All 11 22 22
 Only interventions 4 8 8
 Excl. interventions 7 14 14
Rectal wall point dose (Gy)
 All 5.2 (2.7 – 6.9) 4.8 (2.8 – 10.6) 5.1 (3.0 – 7.5) -0.2 (-3.1 – 0.9) 0.28 0.98
 Only interventions 5.0 (3.6 – 6.4) 5.1 (4.5 – 10.6) 5.2 (4.0 – 7.5) -0.5 (-3.1 – 0.8) 0.24 0.95
 Excl. interventions 5.3 (2.7 – 6.9) 4.5 (2.8 – 6.5) 4.9 (3.0 – 6.2) -0.1 (-0.8 – 0.9) 0.66 1.00
Mesorectum D2cc (Gy)
 All 6.1 (4.8 – 7.2) 6.1 (4.0 – 8.0) 5.8 (3.9 – 7.7) -0.2 (-1.3 – 0.7) 0.15 0.98
 Only interventions 5.2 (4.8 – 7.2) 5.5 (4.0 – 8.0) 5.2 (3.9 – 7.7) -0.4 (-1.3 – 0.6) 0.08 0.94
 Excl. interventions 6.4 (5.8 – 6.8) 6.2 (4.4 – 7.5) 5.9 (4.4 – 7.2) -0.1 (-0.8 – 0.7) 0.65 1.00
Anus D2cc (Gy)
 All 1.7 (0.5 – 3.6) 2.7 (0.4 – 4.5) 3.0 (0.4 – 6.1) 0.2 (-0.8 – 2.3) 0.34 1.07
 Only interventions 2.1 (0.9 – 2.6) 3.2 (0.9 – 4.3) 3.1 (0.9 – 6.1) 0.2 (-0.8 – 2.3) 0.66 1.05
DISCUSSION
The aim of this study was to determine the differences regarding treatment plan conformity, target 
volume coverage and dose to organs at risk between using a single treatment plan for all fractions versus 
a new treatment plan at each fraction in HDREBT for rectal cancer. In this study of eleven patients, 
replanning for each fraction resulted in a significantly more conformal treatment plan and in some cases 
a substantially higher CTV D98 (Table 1). This study shows that for 12/22 repeat CT scans, the projected 
treatment plans met the coverage criteria of CTV D98 being at least 85% of the prescribed dose and at 
least 90% of the CTV D98 of the first fraction. This improved to 14/22 after replanning. An important 
value of repeat CT at each fraction lies in verifying applicator balloon setup and absence of air and/or 
feces in the rectum. This is underlined by the significant effect of intervention required on COIN and 
CTV D98. Although replanning resulted on average in a 31% increase in COIN in the cases that needed 
an intervention, COIN and CTV D98 remain low and demonstrate the limited value of replanning in these 
cases (Table 1). If interventions would have been performed where needed, we expect that treatment 
plan conformity and target volume coverage would have been similar to those cases that did not need an 
intervention. After an intervention, a new repeat CT scan should always be acquired to verify its effect.
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Adding repeat CT planning before each fraction adds approximately one hour per fraction. This includes 
acquiring the CT scan, delineation of target volume and organs at risk and treatment planning. We realize 
that this adaptive approach is labor intensive and may therefore be difficult to implement. Therefore, we 
report on the benefit of an adaptive approach in terms of treatment plan quality to aid in the decision 
whether to implement it or not. Even without replanning, acquiring a repeat CT scan is valuable to verify 
applicator balloon setup and absence of air and/or feces.
As reported, two cases show an increase of CTV D98 of 2.4 Gy and 1.7 Gy after replanning. In the first 
case, this was due to a different insertion angle of the applicator, which led to a different orientation of 
the CTV. In the second case, this was due to a suboptimal balloon orientation and a different insertion 
angle of the applicator, which led to a different orientation of the CTV on the repeat CT scan. Therefore, 
in these two cases, the projected treatment plan partly missed the CTV. Consequently, after replanning, 
the new treatment plan was adapted to the CTV on the repeat CT scan and this resulted in a higher 
CTV D98. One case showed a decrease of CTV D98 of 1.0 Gy and a reduction of the rectal wall point 
dose of 3.1 Gy because the applicator balloon was not inflated on the repeat CT scan, which resulted in 
a more conservative treatment planning for the new treatment plan. In another case, after replanning, a 
decrease of mesorectum D2cc of 1.3 Gy was observed because the CTV orientation was slightly different 
on the repeat CT scan. This resulted in the projected treatment plan partly missing the CTV and covering 
a part of the mesorectum instead. After replanning, the new treatment plan was adapted to the CTV on 
the repeat CT scan, resulting in a lower mesorectum D2cc. An increase of the anus D2cc of 2.3 Gy and 2.1 
Gy for fraction two and three was observed in a patient with a distal tumor. For this specific patient, the 
most caudal slice of the CTV was larger on the repeat CT scans compared to the CTV on the CT scan of 
the first fraction, resulting in lower CTV coverage of the projected treatment plan. Consequently, after 
replanning, the new treatment plan was adapted to the larger CTV and this resulted in a higher anus 
D2cc.
Our conclusions are consistent with a congress abstract of Nout et al. on a cohort of 16 patients [20]. 
Additionally, we report on treatment plan conformity and causes of decreased target volume coverage. 
Similar studies have been performed for image-guided brachytherapy for cervical cancer, which 
conclude that an adaptive approach is necessary to correct for possible changes in applicator and 
anatomy geometry [14,15].
One paper by Devic et al. describes the distribution of the corrections in craniocaudal direction for a 
cohort of 62 patients and shows for one patient what effect it would have on the CTV dose if these 
corrections were not applied [11]. Our study did not evaluate variations in dose as a result of uncertainties 
in applicator positioning correction using X-rays.
Baltas et al. describe the COIN parameter for evaluation of implant quality and dose specification in 
brachytherapy [22]. With HDREBT using an endorectal applicator no implants are involved. As the 
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radiation source is brought next to the tumor instead of into the tumor, the reference isodose volume 
(VRI) will always be substantially larger than the volume of the CTV that is covered by the reference 
isodose (TVRI ). The  component of the COIN equation is therefore very low, resulting in low COIN 
values. This explains the low COIN values reported in this study, compared to the values mentioned in 
Baltas et al. [22]. In our opinion, rather than the absolute value, the ratio of the COIN between projection 
and replanning is informative and a good measure for treatment plan conformity. 
Two factors of the COIN equation are dependent on the absolute delineated volume of the tumor (TV) 
and organs at risk (VCO,i ). However, as comparisons are made between the projection and the replanning 
on the same CT scan, the delineated volumes of the tumor and organs at risk are the same for projection 
and replanning.
There are some limitations in this study. First, the number of patients was small. Secondly, the 
delineations of the CTV are difficult to perform on CT, even with the provided diagnostic MRI scan, 
rectoscopy images, digital rectal examination and inserted endoluminal clips at the proximal and distal 
border of the tumor. No MRI with applicator in situ was available because the endoluminal clips cause 
large artifacts on MRI. Consequently, there may be delineation variation among the CT scans of the 
three fractions. Third, we did not report cumulative dose in this study because only four patients did not 
require an intervention at all three fractions, on which no reliable conclusions can be drawn. Finally, it 
would be difficult to show the clinical benefit for patients in terms of local control or reduction in toxicity. 
However, our results show that without additional imaging, patients would have received a suboptimal 
treatment with substantial underdosage.
CONCLUSION
The results of this study show that using a single CT-based treatment plan for all fractions in HDREBT for 
rectal cancer may result in a suboptimal treatment at later fractions. Therefore, repeat CT imaging should 
be the minimal standard practice in HDREBT for rectal cancer to determine whether an intervention 
would be necessary. Replanning based on repeat CT imaging resulted in more conformal treatment plans 
and is therefore recommended.
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ABSTRACT
Background and purpose
A GTV boost is suggested to result in higher complete response rates in rectal cancer patients, which is 
attractive for organ preservation. Fiducials may offer GTV position verification on (CB)CT, if the fiducial-
GTV spatial relationship can be accurately defined on MRI. The study aim was to evaluate the MRI 
visibility of fiducials inserted in the rectum.
Methods and materials
We tested four fiducial types (two Visicoil types, Cook and Gold Anchor), inserted in five patients each. 
Four observers identified fiducial locations on two MRI exams per patient in two scenarios: without 
(scenario A) and with (scenario B) (CB)CT available. A fiducial was defined to be consistently identified 
if 3 out of 4 observers labeled that fiducial at the same position on MRI. Fiducial visibility was scored on 
an axial and sagittal T2-TSE sequence and a T1 3D GRE sequence.
Results
Fiducial identification was poor in scenario A for all fiducial types. The Visicoil 0.75 and Gold Anchor 
were the most consistently identified fiducials in scenario B with 7 out of 9 and 8 out of 11 consistently 
identified fiducials in the first MRI exam and 2 out of 7 and 5 out of 10 in the second MRI exam, 
respectively. The consistently identified Visicoil 0.75 and Gold Anchor fiducials were best visible on the 
T1 3D GRE sequence.
Conclusions
The Visicoil 0.75 and Gold Anchor fiducials were the most visible fiducials on MRI as they were most 
consistently identified. The use of a registered (CB)CT and a T1 3D GRE MRI sequence is recommended.
INTRODUCTION
Neoadjuvant radiotherapy plays an important role in the treatment of patients with rectal cancer since 
it reduces the rate of local recurrence [1–4]. After standard neoadjuvant chemoradiation, pathological 
complete response is observed in approximately 15-25% of patients [5,6]. In selected centers with a 
watch and wait approach, clinical complete response is observed in up to 50% of patients, probably 
due to better patient selection [7,8]. Dose response analyses suggest that higher tumor doses result 
in higher complete response rates in rectal cancer patients, which is attractive in the light of increased 
interest for organ preservation [6,9–11].
Tumor dose can be increased by applying a boost with external beam radiotherapy (EBRT), high-dose 
rate endorectal brachytherapy (HDREBT) or contact therapy. Current clinical practice for position 
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verification is megavolt imaging or cone beam computed tomography (CBCT) during EBRT and a 
radiograph or CT during HDREBT [12–15]. However, these imaging modalities suffer from limited soft 
tissue contrast which makes position verification of the gross tumor volume (GTV) difficult [16,17]. For 
HDREBT position verification, endoluminal clips have been used to indicate the proximal and distal 
borders of the tumor [18]. However, these clips create large artifacts on magnetic resonance imaging 
(MRI), which makes it impossible to determine the spatial relationship with the GTV accurately using 
MRI [19]. With the introduction of MR-guided radiotherapy systems, position verification of the GTV 
could be performed online with the superior soft-tissue contrast of MRI [20]. However, as MR-guided 
linear accelerators and in room MRI-HDR suites are not widely available, MRI compatible gold fiducials 
in combination with (CB)CT may offer an alternative for position verification of the GTV. The use of 
fiducials has been described for other tumor locations such as pancreas, esophagus and prostate and 
has been proven useful for position verification of the target volume during EBRT [21–23].
To determine the location of the GTV accurately on (CB)CT, the spatial relationship between the GTV 
and the fiducials should be determined on MRI and therefore the fiducials have to be visible on MRI. 
Several studies report good MRI visibility of fiducials in phantoms or other organs [24–26]. However, the 
presence of air and feces in the rectum may hamper fiducial visibility. Excellent fiducial visibility in the 
rectum has been reported on CT, but no analysis of MRI visibility has been performed to date [27,28]. 




Between July 2015 and September 2016, we included 20 patients at the Netherlands Cancer Institute 
(NKI) and at the Leiden University Medical Center (LUMC) with proven rectal adenocarcinoma who were 
scheduled for short-course radiotherapy (SC-RT; 5x5 Gy) or long course chemoradiotherapy (LC-CRT; 
25x2 Gy combined with capecitabine 825 mg/m² twice daily) followed by a total mesorectal excision. 
Eleven patients received SC-RT and nine patients LC-CRT. Exclusion criteria were contraindication 
for fiducial insertion (coagulopathy or anticoagulants that cannot be stopped), prior pelvic irradiation, 
pelvic surgery or hip replacement surgery, pregnancy, world health organization performance status 3-4 
and a contraindication for MRI. This study was registered at the Dutch Trial Registry (REMARK study, 
registration no. NTR4606) [29].
Fiducials
We tested four types of fiducials, inserted in five patients each (Visicoil 0.5 mm x 5 mm and Visicoil 
0.75 mm x 5 mm [IBA Dosimetry, GmbH, Germany], Cook 0.64 mm x 3.4 mm [COOK Medical, Limerick, 
Ireland] and Gold Anchor 0.28 mm x 20 mm (unfolded length)[Naslund Medical AB, Sweden]. The 
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Visicoil and Cook fiducials were straight, only differing in diameter and length. The Gold Anchor fiducial 
was also straight but could be folded when inserted, depending on the insertion technique. We have 
inserted the Gold Anchor fiducial in a folded configuration as it improves MRI visibility [24].
Four experienced gastroenterologists (two in each center) inserted 64 fiducials in 20 patients in the 
tumor or mesorectum at least one day before the start of radiotherapy by sigmoidoscopy or endoscopic 
ultrasonography. The target lesion was visualized and the absence of intervening vascular structures 
was verified before inserting each fiducial. In the first 10 patients, we aimed to insert three fiducials in 
the tumor tissue. Due to limited fiducial retention in these patients, in the last 10 patients we aimed to 
insert at least two fiducials in the mesorectal fat (one proximal and one distal of the tumor) and one in 
the center of the tumor.
Imaging
We acquired a planning CT scan before the start of radiotherapy on a Siemens Sensation Open (slice 
thickness 3.0-5.0 mm, pixel spacing 0.98-1.27 mm x 0.98-1.27 mm, 120 kVp, tube current 74-307 mA 
(automatic exposure control), exposure time 1100 ms, convolution kernel B40s) or a Philips Brilliance 
Big Bore (slice thickness 3.0 mm, pixel spacing 0.98-1.14 mm x 0.98-1.14 mm, 120 kVp, tube current 271 
mA, exposure time 923 ms, convolution kernel B (Philips)). To evaluate reproducibility of fiducial visibility 
on MRI, we performed a pre-treatment MRI exam before the start of radiotherapy (from now on called 
first MRI) and a second MRI exam after completion of a week of radiotherapy (from now on called second 
MRI). MRI exams were performed in supine position on a standard MR table. Due to logistical reasons, 
for one patient a second MRI was not performed. MRI exams were performed on a Philips Achieva 1.5T, 
Philips Achieva 3T, Philips Achieva dStream 3T or a Philips Ingenia 3T. Two MRI exams were performed 
on the 1.5T MRI scanner, all other MRI exams were performed on 3T MRI scanners. We selected three 
MRI sequences for the fiducial visibility scoring, including a transverse 2D T2 turbo spin echo sequence 
(tT2-TSE), a sagittal 2D T2-TSE sequence (sT2-TSE) and a T1 3D gradient echo sequence (T1 3D GRE). 
The T1 3D GRE sequence was acquired with fat suppression in 16/20 scans in the first MRI and 14/19 
scans in the second MRI. Scan parameters for the different MRI sequences are reported in Table I in the 
supplementary materials.
During the first week of radiotherapy, we acquired daily pre- and post-irradiation CBCT scans 
(reconstructed slice thickness 1.0 mm, pixel spacing 1.0 mm x 1.0 mm, 120 kVp, tube current 32 mA, 
exposure time 40 ms). Before the planning CT and each radiotherapy fraction, patients were asked to 
void their bladder and subsequently drink 300 cc of water to reproduce bladder filling.
As all fiducials were well visible on (CB)CT, we registered and subsequently resampled a (CB)CT scan 
to the T1 3D GRE sequence of each MRI exam with a rigid registration with a mutual information metric 
using Elastix [30]. The registration was assessed by a single observer (RE) by checking the alignment of 
the bony anatomy. We used the (CB)CT scan that was acquired closest to the acquisition date of the MRI 
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exam. The T1 3D GRE sequence was chosen for the registration as it had the highest resolution. As all 
MRI sequences were acquired within the same MRI exam without table movement between sequences, 
no registration was performed between the sequences. 
Images were visualized with an in-house developed user interface, created in MeVisLab 2.7.1 (MeVis 
Medical Solutions AG, Fraunhofer MEVIS, Bremen, Germany). The user interface automatically determines 
a window/level setting depending on the image set that is shown. The automatically determined window 
was defined as the difference between the minimum and maximum image pixel value and the level was 
defined as the mean of the minimum and maximum image pixel value. All observers were therefore 
presented with images with initially the same window/level settings when performing the fiducial 
visibility scoring. In addition, observers were able to manually change the window/level settings.
Fiducial visibility scoring
Fiducial visibility was scored by two radiologists with expertise in rectal imaging (EP and DL), a radiation-
oncologist (BT) and a resident radiation-oncologist (ER). Observers were blinded for fiducial type and 
each other’s results.
Fiducial visibility was scored according to two scenarios. In scenario A, only the MRI images and clinical 
information (endoscopic findings and number and location of inserted fiducials) were available to the 
observers. In scenario B, the MRI images, clinical information as well as the rigidly registered CB(CT) scan 
were at the observer’s disposal. For the first MRI, visibility scoring according to scenarios A and B was 
subsequently performed within one scoring session; for the second MRI, only scenario B was performed.
For each scenario, the observers first scored the fiducials on the first MRI for each patient and at a 
later stage on the second MRI for each patient. For both MRI exams the observers analyzed patients 
in random patient order. The observers rated the fiducial visibility on each available MRI sequence (not 
visible, poor/average or good/excellent) and rated how confident they were that the identified fiducial 
position really represented a fiducial and not for example an air artifact (not very confident, moderately 
confident, or very confident). Observers were then instructed to identify and label fiducial positions on 
the MRI sequence on which they could identify the fiducial location most accurately. Identified fiducial 
positions were saved in world coordinates. 
We used the (CB)CT as a reference to determine the number of fiducials present in a patient at the time 
of the MRI exam. In combination with the soft tissue information from the MRI scan, we determined 
whether the fiducial was inserted in the tumor or the mesorectum. (CB)CT was not used as a reference 
to determine the position of the fiducials on MRI because of the limited soft tissue contrast which made 
deformable registration with MRI not feasible. Instead, the standard of reference for fiducial location on 
MRI was defined as the consistent identification of a fiducial on the same position on MRI by at least three 
out of four observers. This was determined by calculating the distances between the identifications of 
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all observers using the world coordinates of the identifications. Identification pairs with a distance of 
less than 5 mm between observers were subsequently analyzed visually to check whether the same 
artifact was labeled.
Statistical analysis
We used SPSS Statistics 23 (IBM Corp. Released 2015. IBM SPSS Statistics for Windows, Version 
23.0. Armonk, NY: IBM Corp.) for statistical analysis. The Wilcoxon signed rank test was used to test 
for differences in visibility rating between MRI sequences. All tests were two-sided and the significance 
threshold was set at 0.05.
RESULTS
A total of 64 fiducials was inserted in 20 patients. A planning CT with fiducials was available in 10/20 
patients. In the other 10 patients, fiducials were inserted after the planning CT. Median time between 
fiducial insertion and the first MRI exam was 3 days (range 0-11 days), between any MRI exam and the 
corresponding reference scan 0 days (range 0-5 days) and between the first and second MRI exam 7 
days (range 4-21). At the time of the first MRI, 39 fiducials were still in situ in the tumor or mesorectum, 
based on evaluation on (CB)CT. At the time of the second MRI, 35 fiducials were still in situ. The 
remaining 29 fiducials were either lost between insertion and the first MRI (n=18), lost between the 
two MRI exams (n=4), inadvertently inserted in the prostate (n=5), or simultaneously ejected during 
insertion and therefore so close together that they were analyzed as one fiducial (n=2). For the nine 
patients that received LC-CRT, the CBCT scans that were acquired after the first week of radiotherapy 
showed that no further fiducials were lost during the course of treatment. Nine fiducials were inserted 
in the mesorectum (one Visicoil 0.5, two Visicoil 0.75, three Cook and three Gold Anchor fiducials) and 
thirty fiducials were inserted in the tumor (eight Visicoil 0.5, seven Visicoil 0.75, six COOKs and nine Gold 
Anchors). In five out of nine mesorectum fiducials in four patients a T1 3D GRE sequence was performed 
with fat suppression and therefore these fiducials were excluded from further analyses (one Visicoil 0.5, 
three COOKs and one Gold Anchor). None of these fiducials were consistently identified. An overview of 
patient characteristics, type of reference scan and number of fiducials on reference scan is provided for 
each patient in Table 1. All registrations of (CB)CT scans to corresponding MRI exams were assessed by 
a single observer (RE) and considered to be sufficiently aligned for the purpose of this study: giving an 
approximate location of the fiducial on MRI.
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Table 2 shows an overview of the consistent and inconsistent fiducial identifications with corresponding 
confidence levels. In scenario A of the first MRI, 2/9 Visicoil 0.75, 1/6 Cook and 5/11 Gold Anchor fiducials 
were consistently identified with an average distance between identifications of 1.8 mm (range 0.0 – 
3.8 mm). Of those, two Visicoil 0.75, one Cook and four Gold Anchor fiducials were subsequently also 
consistently identified in scenario B. In scenario B of the first MRI, a total of 17 fiducials were consistently 
identified with an average distance between identifications of 2.0 mm (range 0.0 – 5.1 mm). 
Table 2. Number of consistent and inconsistent identifications for all observers for scenario B with corresponding 
confidence levels, split according to fiducial type. 
Visicoil 0.5 Visicoil 0.75 COOK Gold Anchor
FIRST MRI EXAM, scenario B
Fiducials on corresponding (CB)CT 8 9 6 11
Total identifications by 4 observers* 22 (32) 34 (36) 26 (24) 43 (44)
Inconsistent identifications 19 13 22 14
Consistent identifications 3 21 4 29
 Which represent number of 
 consistently identified fiducials 1 / 8 (13%) 7 / 9 (78%) 1 / 6 (17%) 8 / 11 (73%)
 Of which were already consistently
 identified in scenario A 0 / 8 (0%) 2 / 9 (22%)
 
1 / 6 (17%) 5 / 11 (45%)
Confidence level for all identifications
 not very confident 9 (41%) 2 (6%) 12 (46%) 6 (14%)
 moderately confident 7 (32%) 10 (29%) 7 (27%) 7 (16%)
 very confident 6 (27%) 22 (65%) 7 (27%) 30 (70%)
SECOND MRI EXAM, scenario B
Fiducials on corresponding (CB)CT 7 7 6 10
Total identifications by 4 observers* 22 (28) 25 (28) 20 (24) 40 (40)
Inconsistent identifications 18 19 17 23
Consistent identifications 4 6 3 17
 Which represent number of 
 consistently identified fiducials 1 / 7 (14%) 2 / 7 (29%) 1 / 6 (17%) 5 / 10 (50%)
Confidence level for all identifications
 not very confident 4 (18%) 3 (13%) 9 (45%) 7 (18%)
 moderately confident 3 (14%) 9 (39%) 7 (35%) 21 (52%)
 very confident 15 (68%) 11 (48%) 4 (20%) 12 (30%)
*Numbers between brackets indicate the maximum number of correct identifications by four observers.
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Figure 1. Examples of fiducials shown on (CB)CT and corresponding MRI sequences.
Because of the low number of consistently identified fiducials in scenario A compared to scenario B, 
scenario A was not performed for the second MRI. For the second MRI, nine fiducials were consistently 
identified with an average distance between identifications of 0.9 mm (range 0.0 – 1.9 mm). In scenario B, 
the Visicoil 0.75 and the Gold Anchor fiducials were the most consistently identified fiducial types with 
7/9 fiducials in 4 patients and 8/11 fiducials in 5 patients in the first MRI and 2/7 fiducials in 2 patients 
and 5/10 fiducials in 4 patients in the second MRI, respectively. Examples of fiducials on (CB)CT and 
corresponding MRI sequences are shown in Figure 1. The fiducials shown in Figure 1 were consistently 
identified. Table 3 shows the difference between observers for the Visicoil 0.75 and Gold Anchor fiducial 
identifications. Observer 4 had a substantially lower number of consistently identified fiducials and 
labeled more fiducials on MRI than the number of fiducials present on the reference scan. For observer 
3 and 4 in the second MRI of the Visicoil 0.75, one confidence level was missing.
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Table 3. Number of consistently identified Visicoil 0.75 and Gold Anchor fiducials with corresponding confidence 
levels for each observer.
Observer 1 Observer 2 Observer 3 Observer 4
Visicoil 0.75
FIRST MRI EXAM, scenario B
Number of identifications 7 / 9 7 / 9 9 / 9 11 / 9
 Of which are consistently 
 labeled identifications 6 7 7 1
Confidence level for all identifications
 not very confident 1 (14%) 0 (0%) 0 (0%) 1 (9%)
 moderately confident 2 (29%) 2 (29%) 3 (33%) 3 (27%)
 very confident 4 (57%) 5 (72%) 6 (67%) 7 (64%)
SECOND MRI EXAM, scenario B
Number of identifications 5 / 7 4 / 7 7 / 7 9 / 7
 Of which are consistently 
 labeled identifications 2 2 2 0
Confidence level for all identifications
 not very confident 1 (20%) 1 (25%) 0 (0%) 1 (13%)
 moderately confident 1 (20%) 3 (75%) 4 (67%) 1 (13%)
 very confident 3 (60%) 0 (0%) 2 (33%) 6 (75%)
Gold Anchor
FIRST MRI EXAM, scenario B
Number of identifications 10 / 11 9 / 11 12 / 11 12 / 11
 Of which are consistently 
 labeled identifications 7 8 8 6
Confidence level for all identifications
 not very confident 2 (20%) 1 (11%) 1 (8%) 2 (17%)
 moderately confident 2 (20%) 1 (11%) 2 (17%) 2 (17%)
 very confident 6 (60%) 7 (78%) 9 (75%) 8 (67%)
SECOND MRI EXAM, scenario B
Number of identifications 8 / 10 8 / 10 11 / 10 13 / 10
 Of which are consistently 
 labeled identifications 5 5 5 2
Confidence level for all identifications
 not very confident 3 (38%) 0 (0%) 0 (0%) 4 (31%)
 moderately confident 3 (38%) 5 (63%) 5 (46%) 8 (62%)
 very confident 2 (25%) 3 (38%) 6 (55%) 1 (8%)
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The visibility rating for the consistently identified Visicoil 0.75 and Gold Anchor fiducials per MRI 
sequence for both MRI exams is shown in Table 4. For the Visicoil 0.75, in the first MRI the tT2-TSE 
scored better visibility compared to the sT2-TSE sequence (p=0.03). The T1 3D GRE sequence scored 
better visibility compared to the tT2-TSE (p=0.03) and the sT2-TSE (p=0.01). In the second MRI, T1 3D 
GRE scored better visibility compared to the sT2-TSE (p=0.04). For the Gold Anchor, in the first MRI the 
T1 3D GRE scored better visibility compared to the sT2-TSE (p=0.02). No other statistically significant 
differences were observed. In addition, Table 4 shows on which MRI sequence the fiducial positions 
were labeled, which is the sequence on which the fiducial could most accurately be identified according 
to the observers. For both the Visicoil 0.75 and the Gold Anchor fiducials, the T1 3D GRE sequence was 
chosen most often in both MRI exams.
DISCUSSION
The aim of this study was to evaluate the MRI visibility of different fiducials inserted in the tumor or 
mesorectum. The results show that there are substantial differences in the number of consistently 
identified fiducials between fiducial types. For both the Visicoil 0.5 and the COOK fiducials, only one 
fiducial was consistently identified in both MRI exams (Table 2). These fiducial types were the smallest 
included in this study, which may explain the poor MRI visibility. This result confirms that of a study by 
Chan et al. who described the visibility of different types of fiducials in a phantom on CBCT, CT, megavolt 
imaging and MRI [26]. The authors concluded that fiducials with a diameter of 0.5 mm are poorly visible 
on MRI, even in a phantom. The Visicoil 0.75 has a larger diameter compared to the Visicoil 0.5 and 
the Cook fiducial, which may explain the better performance of this fiducial. The performance of the 
Gold Anchor fiducial is in line with a study by Gurney-Champion et al., who evaluated and characterized 
the visibility of different fiducials in a phantom on CT and MRI and included an in-vivo analysis of four 
patients in whom fiducials were inserted in the pancreas [24]. The authors recommend a Gold Anchor 
fiducial in a folded configuration when MRI visibility is desired.
The fiducial insertion strategy was changed during the study because insertion of fiducials in the 
tumor resulted in a low fiducial retention rate. Since only nine out of 39 fiducials were inserted in the 
mesorectum and five of those were scanned with fat suppression on the T1 3D GRE sequence, no firm 
conclusions can be drawn on the difference in fiducial detection between fiducials in the tumor and the 
mesorectum.
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Table 4. Visibility rating per MRI sequence for the consistently identified Visicoil 0.75 and Gold Anchor fiducials in 
scenario B of both MRI exams. In addition, the MRI sequence on which the fiducial positions were labeled is shown.
tT2-TSE sT2-TSE T1 3D GRE
Visicoil 0.75
FIRST MRI EXAM, scenario B
not visible 1 (5%) 6 (29%) 0 (%)
poor/average 12 (57%) 7 (33%) 9 (43%)
good/excellent 8 (38%) 8 (38%) 12 (57%)
Labeled sequence 2 / 21 (10%) 2 / 21 (10%) 17 / 21 (81%)
SECOND MRI EXAM, scenario B
not visible 0 (0%) 4 (67%) 0 (0%)
poor/average 4 (67%) 1 (17%) 2 (33%)
good/excellent 2 (33%) 1 (17%) 4 (67%)
Labeled sequence 0 / 6 (0%) 1 / 6 (17%) 5 / 6 (83%)
Gold Anchor
FIRST MRI EXAM, scenario B
not visible 3 (10%) 4 (14%) 2 (7%)
poor/average 9 (31%) 10 (35%) 5 (17%)
good/excellent 17 (59%) 15 (52%) 22 (76%)
Labeled sequence 8 / 29 (28%) 4 / 29 (14%) 17 / 29 (59%)
SECOND MRI EXAM, scenario B
not visible 1 (6%) 3 (18%) 1 (6%)
poor/average 5 (29%) 7 (41%) 6 (35%)
good/excellent 11 (65%) 7 (41%) 10 (59%)
Labeled sequence 0 / 17 (0%) 7 / 17 (41%) 10 / 17 (59%)
Eight out of eleven Gold Anchor fiducials were consistently identified in the first MRI, while only five out 
of ten Gold Anchors fiducials were consistently identified in the second MRI (Table 2). One identified 
Gold Anchor fiducial was lost in between the MRI exams, as evaluated on CBCT. For the two Gold Anchor 
fiducials in two patients that were no longer identified in the second MRI, the first and the second MRI 
were compared. Air or feces deformed the rectum which made correlation with the CBCT scan difficult. 
In addition, the artifacts caused by air further hampered fiducial detection. For the Visicoil 0.75, only two 
out of seven fiducials were consistently identified in the second MRI, compared to seven out of nine in 
the first MRI. Two consistently identified fiducials were lost in between the MRI exams. The remaining 
three fiducials were no longer consistently identified in the second MRI as they were identified by only 
two out of four observers.
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Even with the two best visible fiducials in this study, it can be argued whether the obtained performance 
justifies the use of fiducials in the rectum in clinical practice. For instance, reproducibility of the observer 
identifications between the MRI exams was limited, as shown by the lower number of consistently 
identified fiducials in the second MRI for Visicoil 0.75 and Gold Anchor. In addition, inconsistencies 
between observers were observed, especially for the Visicoil 0.75 (Table 3). This suggests that it is 
worthwhile to have at least two observers to identify the fiducial positions on MRI. Furthermore, more 
fiducials may be inserted to increase the chance that sufficient fiducials will be identified for position 
verification (e.g. two or three).
The anatomical 2D T2-TSE sequences scored lower visibility with the Visicoil 0.75 fiducials compared 
to the Gold Anchor fiducials. This may be explained by the smaller size of the Visicoil 0.75 fiducials, 
which results in smaller signal voids on MRI. The signal voids may have been too small on the T2-TSE 
sequences. It is therefore not sufficient to use these MRI sequences alone to identify fiducial positions 
on MRI. The T1 3D GRE sequence scored higher fiducial visibility for both MRI exams for the Visicoil 0.75 
and the first MRI exam for the Gold Anchor and was most often chosen to label the fiducial position on 
in all cases (Table 4). It is therefore recommended to include a T1 3D GRE sequence.
The T1 3D GRE sequence was a single-echo sequence acquired with a TE of about 2 ms. Two studies 
that evaluated fiducial visibility in the prostate reported promising results on the use of a multi-echo 
gradient echo sequence [25,31]. The multi-echo gradient echo sequence results in multiple image sets 
with increasing TE which results in increased signal void size. It could be worthwhile to include this 
sequence in future studies, possibly enhancing fiducial identification.
Moningi et al. evaluated the role of fiducials in patients receiving neo-adjuvant endorectal brachytherapy 
in 11 rectal cancer patients [28]. The visibility of two types of fiducials was evaluated on CT by a 
radiologist, in which a subjective scoring system similar to this study was used. The radiologist scored all 
fiducials as clearly visible. The authors mention that both types of fiducials created a void on MRI that 
could assist with treatment planning, but no similar visibility analysis was performed to support this 
statement.
This study focused on gold fiducials, while other types of fiducials might be of interest. Liquid markers 
such as a hydrogel marker were not included because of poor stability, most likely because of absorption 
in the tissue [32]. Recent studies report on a liquid marker that forms a semisolid gel after injection 
[33,34]. Rydhog et al. reports on 15 lung cancer patients in whom markers were injected in the lymph 
nodes or the tumor. The authors found that the markers were well visible on CT and CBCT and stable in 
size and position throughout the treatment [33]. Schneider et al. evaluated gold fiducials and the liquid 
marker in a gel phantom that mimics the relaxation properties of pancreatic tissue. The authors show 
that the liquid markers cause signal voids on MRI due to the absence of water protons, equally affecting 
all MRI sequences [34]. This is contrary to gold fiducials, which also cause signal voids due to their effect 
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on T2* of the surrounding tissue [24]. Therefore, the potential visibility of gold fiducials and the artifact 
size are correlated. As a result, better gold fiducial visibility because of increased TE also results in larger 
artifacts caused by air.
There are some limitations to this study. Only 39 fiducials were available for the visibility analysis because 
some fiducials were lost between insertion and the first MRI and five fiducials were inadvertently 
inserted in the prostate. Because of the low number of available fiducials per fiducial type, no statistical 
tests were performed to test for differences in consistent identifications between fiducial types.
The observers were blinded for fiducial type. As the artifact size differs substantially between fiducial 
types, results might have been better if observers had known what artifact size to look for [24]. Since 
we defined a fiducial consistently identified if at least three out of four observers identified that fiducial 
position on the same position on MRI, inconsistently identified fiducials may still be true fiducials, but 
only identified by one or two observers. 
There is no gold standard for the location of the fiducials on MRI. The rigid registration with (CB)CT 
provides an estimation of the location and may be inaccurate when day-to-day differences in rectal 
position and shape occur. Non-rigid registration was attempted for both the planning CT and CBCT 
scans, but was not considered feasible because of limited soft-tissue contrast, particularly on CBCT (35 
out of 39 reference scans). Additionally, differences in rectal filling and differences in the presence and 
volume of air in the rectum further hampered non-rigid registration. Clinical practice does not include 
instructions on a diet or voiding of the rectum before the radiotherapy fraction. In addition, voiding of the 
bladder and drinking instructions were not applied before the MRI exam. If the drinking protocol would 
be applied to MRI and instructions on a diet or voiding of the rectum would be used, the correspondence 
between patient anatomy on CBCT and MRI may improve.
In conclusion, the Visicoil 0.75 and Gold Anchor fiducials were the best visible fiducials on MRI as it were 
the most consistently identified fiducials. Anatomical 2D T2-TSE MRI sequences are not sufficient to 
identify fiducials. Therefore, a T1 3D GRE sequence is recommended. The use of a corresponding (CB)
CT scan improves fiducial detection on MRI. However, even for the best two fiducial types in this study, 
fiducial identification on MRI is challenging as shown by limited reproducibility between MRI exams and 
inconsistencies between observers. It is therefore recommended to have at least two observers and to 
further optimize MRI sequences to enhance the visibility of the fiducials.
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ABSTRACT
Purpose
The individual channels in an endorectal applicator for high-dose-rate endorectal brachytherapy are not 
visible on standard MRI sequences. The aim of this study was to test whether an ultrashort echo time 
(UTE) MRI sequence could be used to visualize the individual channels to enable MR-only treatment 
planning for rectal cancer.
Methods and materials
We used a radial 3D UTE pulse sequence and acquired images of phantoms and two rectal cancer 
patients. We rigidly registered a UTE image and CT scan of an applicator phantom, based on the outline 
of the applicator. One observer compared channel positions on the UTE image and CT scan in five slices 
spaced 25 mm apart. To quantify geometric distortions, we scanned a commercial 3D geometric QA 
phantom and calculated the difference between detected marker positions on the UTE image and 
corresponding marker positions on two 3D T
1
-weighted images with opposing readout directions. 
Results
On the UTE images, there is sufficient contrast to discern the individual channels. The difference in 
channel positions on the UTE image compared to the CT was on average -0.1 ± 0.1 mm (LR) and 0.1 ± 
0.3 mm (AP). After rigid registration to the 3D T
1
-weighted sequences, the residual 95th percentile of the 
geometric distortion inside a 550 mm diameter sphere was 1.0 mm (LR), 0.9 mm (AP) and 0.9 mm (CC).
Conclusions
With a UTE sequence, the endorectal applicator and individual channels can be adequately visualized in 
both phantom and patients. The geometrical fidelity is within acceptable range.
INTRODUCTION
For rectal cancer patients, high-dose rate endorectal brachytherapy (HDREBT) can be used to deliver 
high doses to the tumor while sparing surrounding organs at risk due to a steep dose gradient [1]. 
HDREBT may be delivered using an intracavitary mold applicator set, such as the flexible eight-channel 
applicator (Elekta, Veenendaal, the Netherlands). Applicator reconstruction for the flexible eight-
channel applicator is currently performed on CT [2,3], because the individual channels of the applicator 
are not visible on conventional MR images due to the short T
2
-relaxation time of the applicator. However, 
CT suffers from limited soft-tissue contrast, which makes it challenging to delineate the target volume 
accurately [4,5]. MRI is the primary imaging modality for tumor visualization because of its superior 
soft-tissue contrast and it is therefore currently registered to CT imaging to aid in the tumor delineation 
on CT. However, acquiring both CT and MRI on the same day can be time consuming and changes in 
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applicator positioning between the scans may occur because of patient movement and/or differences in 
organ filling. An MRI-only approach in which applicator reconstruction, delineation of target volume and 
organs at risk, and treatment planning is performed on MRI is therefore preferred. 
MRI-only brachytherapy treatment planning is already the standard for cervical cancer in Europe [6]. 
To perform applicator reconstruction on MRI, models of rigid applicators have been made available in 
commercial treatment planning systems and these can be rigidly registered to the applicator on MR 
images. However, for non-rigid applicators such as the flexible endorectal applicator, such models are 
not available. In addition, since the individual channels of the flexible endorectal applicator are not 
visible on MRI, the rotation of the applicator cannot be determined because of its cylindrical shape. In 
brachytherapy for cervical cancer, dummy catheters can be used to aid in applicator reconstruction. The 
dummy catheter is filled with a fluid that produces high signal intensity on MRI. However, such dummy 
catheters are not available for the flexible endorectal applicator. As an alternative, an ultrashort echo 
time (UTE) sequence [7,8] may be used to visualize the applicator and the individual channels. UTE uses 




The aim of this study was to test if a UTE sequence can be used to visualize the individual channels 
within the flexible endorectal applicator for HDREBT treatment planning. To this end, we first evaluated 
the visibility of the individual channels in a phantom and determined the geometric fidelity of the UTE 
sequence. Finally, we acquired UTE images from two rectal cancer patients with applicator in situ to 
evaluate the visibility of the individual channels in an applicator in situ.
METHODS AND MATERIALS
Applicator
We used a commercial intracavitary mold applicator (OncoSmart, Elekta, Veenendaal, The Netherlands). 
This is a flexible cylindrical applicator made of silicon with a diameter of 20 mm and a length of 280 
mm. The applicator has eight channels radially spaced along its circumference, which allows for an 
asymmetric dose distribution [9].
UTE sequence
All MRI scans in this study were performed on a 3T scanner (Ingenia, Philips Healthcare, Best, The 
Netherlands). We used a 3D stack of radials UTE pulse sequence for radial sampling of free induction 
decays, enabled by clinical science functionality under a research agreement. A cylindrical encoding 
scheme was performed with radial sampling in-plane and cartesian sampling through-plane. Radial 
sampling was used as it allows for very short echo times in the order of <0.5 ms. The sequence is similar 
to the stack of spirals UTE sequence described in Qian et al. [10]. For UTE excitation, a non-selective 
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hard radiofrequency pulse was applied for a very short duration (0.05 ms) and was followed by a 
phase-encoding gradient in craniocaudal (CC) direction for slice encoding. Immediately after the phase-
encoding gradient, a radial read-out was performed to quickly sample the k-space in the two directions 
that are perpendicular to the slice direction. The radial k-space data acquisition started already during 
the ramp of the gradients [7]. The scan parameters for the UTE sequences used for imaging the 
applicator phantom, the two patients, and the geometric QA phantom are shown in Table 1. To ensure 
clinical feasibility, the scanning times for patients were kept below 6 minutes.
Applicator phantom
To optimize and evaluate the UTE sequence for applicator visualization, we prepared a phantom. We 
first filled a box (400 x 300 x 190 mm³) halfway with agarose gel. The agarose gel consisted of 0.2 g 
Dotarem 0.5 mM (Guerbet, Villepinte, France), 10 grams agar (A1296, Sigma Aldrich, Saint Louis, USA), 
and 3 grams NaCl per liter water, aiming for a T
1
 (spin-lattice relaxation time) of 1-2 seconds and a T
2
 
(spin-spin relaxation time) of >30 ms [11], which is on the same order of magnitude as the relaxation 
properties of human soft-tissue around the rectum. A balloon was placed around the applicator and 
subsequently filled with 20cc of water with 5% Telebrix Gastro (Guerbet, Villepinte, France), as in our 
clinical procedure. The applicator was then placed on top of the first layer of agarose gel and a second 
layer of agarose gel was applied to fill the box.
Individual channel visualization
To evaluate the visibility of the individual channels within the applicator, we acquired an axial UTE 
image of the phantom. To test whether the visualized channels on the UTE image actually represent 
the individual channels within the applicator, we acquired an axial CT scan (Brilliance Big Bore, Philips 
Healthcare, Best, The Netherlands) of the phantom (voxel size 0.63 x 0.63 x 1 mm3, 120 kVp, tube 
current 346 mA, exposure time 887 ms). We performed a rigid registration of the CT scan to the UTE 
Table 1. Scan parameters for the UTE sequences used for imaging the applicator phantom, the patients, and the 
geometric fidelity phantom.
Parameter Applicator phantom Patient 1 Patient 2 Geometric QA phantom
Voxel size (mm3) 1.0x1.0x2.5 1.0x1.0x3.5 0.98x0.98x2.5 1.94x1.94x1.94
Echo time (ms) 0.14 0.14 0.14 0.14
Repetition time (ms) 5.26 4.97 5.22 4.22
Acquisition grid 376x376x126 376x376x90 384x384x90 288x288x206
Field of view (mm3) 376x376x315 376x376x315 376x376x225 560x560x400
Readout bandwidth (Hz/mm) 886 886 886 895
SENSE factor 1.4 1.4 1.4 1.0
Flip angle (deg) 10 10 10 10
Acquisition duration (s) 499 337 353 643
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image based on the outline of the applicator using Elastix, a toolbox for intensity-based medical image 
registration [12]. To determine channel positions, one observer manually aligned a 2D template of the 
channel configuration on the UTE image and the registered CT scan in five slices spaced 25 mm apart. 
We then calculated the in-plane difference in channel positions between the UTE image and the CT 
scan. To evaluate the visibility of the channels in a clinical setting, we acquired informed consent from 
two rectal cancer patients undergoing HDREBT within a clinical trial. In addition to the MRI sequences 
acquired for HDREBT treatment planning, we acquired an additional axial UTE image for these two 
patients with the applicator in situ. As part of sequence optimization, we acquired a UTE image with 
a slice thickness of 3.5 mm in the first patient and a slice thickness of 2.5 mm in the second patient. 
For one slice in each UTE image, we determined the contrast-to-noise ratio (CNR = |SC – SA |/σ)  of 
the channels relative to the applicator. Here, SC and SA are the average signal intensities of the channels 
and the applicator, respectively, and σ is the standard deviation of the image noise. Average signal 
intensities were extracted from regions of interest of 2 x 2 mm placed on and between the channels. In a 
similar fashion, σ was estimated from signal intensity variations inside a region of interest in the balloon 
surrounding the applicator. 
Geometric fidelity
To quantify geometric distortions, we acquired MRI images of a commercial 3D geometric QA phantom 
(Philips Healthcare, Best, The Netherlands) [13,14]. The phantom was placed on the treatment table 
centered around the isocenter. It consists of seven plastic plates, placed 55 mm apart, each containing 
276 spheres (markers) filled with oil with a diameter of 10 mm. Within each plate, the markers are located 
on a grid with a spacing of 25 mm. In total, the phantom is 330 mm long and has a diameter of 500 mm.
To determine the actual position of the markers within the phantom, we used two axial 3D T
1
-weighted 
gradient-echo sequences (voxel size: 1.94 mm x 1.94 mm x 1.94 mm, field of view: 560 x 560 x 400 mm3, 
TE: 3.40 ms, TR: 6.90 ms, readout bandwith: 828 Hz/mm) with opposing readout directions (anterior 
and posterior) to be able to correct for magnetic-field inhomogeneity. Subsequently, we acquired a UTE 
image with the same isotropic voxel size as the two axial 3D T
1
-weighted images (Table 1). The marker 
detection algorithm described in Keesman et al. [13] was used to detect the markers, which produced 
lists of marker positions, one for each image. 
To correct for magnetic-field inhomogeneity, the corresponding detected marker positions in the 
two 3D T
1
-weighted images were averaged. To assess the distortion of the averaged 3D T
1
-weighted 
marker positions, a regular reference grid (containing the ideal marker positions, defined according to 
the known geometry of the phantom) was rigidly registered per plate to the averaged 3D T
1
-weighted 
marker positions. Residuals between the averaged 3D T
1
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To assess the geometric distortion of the UTE image relative to the 3D T
1
-weighted images, we calculated 
the residuals between detected markers in the UTE image and ref_grid
T1_3D
. The 5th, 50th and 95th 
percentiles for the residuals are presented for various diameters of spherical volume (DSV) to evaluate 
the geometric fidelity for various distances from the isocenter.
RESULTS
Individual channel visualization
On the UTE image that was acquired of the applicator phantom, the channels have sufficient contrast 
relative to the applicator itself to be able to discern the individual channels (Figure 1). The difference in 
channel positions on the UTE image compared to the CT was on average -0.1 ± 0.1 mm (left-right (LR)) 
and 0.1 ± 0.3 mm (anteroposterior (AP)). In addition, individual channels are visible on the UTE patient 
images (Figure 2). CNR was calculated from the slices that contained the balloon (Figure 2, A2 and B2). 
The CNR was 1.9 for patient 1 and 2.4 for patient 2.
Geometric distortion
In total, 1428 corresponding markers out of the 1932 markers in the geometric QA phantom were 
detected by the marker detection algorithm in both the 3D T
1
-weighted images and the UTE image. 
Marker appearance on the UTE image and the 3D T 
1
-weighted images with opposing readout directions 
is shown in Figure 3. The mean and standard deviation of the residuals between the averaged 3D T
1
-
weighted marker positions and ref_grid
T1_3D
 was 0.01 ± 0.42 mm (LR), -0.03 ± 0.36 mm (AP), and 0.02 ± 
0.33 mm (CC). The 95th percentile of the residuals was 0.81 mm (LR), 0.68 mm (AP), and 0.65 mm (CC) 
within a DSV of 550 mm, which includes all detected markers. In Figure 4, the residuals are plotted as a 
function of distance to the isocenter in the LR, AP and CC directions, respectively.
The mean and standard deviation of the residuals between detected markers in the UTE image and ref_
grid
T1_3D
 were 0.46 ± 0.46 mm (LR), -1.69 ± 0.50 mm (AP), and 0.07 ± 0.48 mm (CC). This indicates a 
systematic shift, mostly in the AP direction. In a clinical scenario, a rigid registration is performed between 
the UTE image and an anatomical image based on the outline of the applicator to correct for any changes 
in patient and/or applicator positioning that can occur within the scan session. To investigate effects 
of higher-order distortion patterns in the UTE image, we corrected this systematic shift by means of a 
global translation. Subsequently, we calculated the remaining residuals. The 5th, 50th and 95th percentiles 
for these residuals within various DSVs are presented in Table 2. A 95th percentile of 1.0 mm or lower 
is observed in all directions within a DSV of 550 mm. The magnitude of the distortions increases with 
increasing distance from the isocenter. This can also be observed in Figure 4, where the residuals are 
plotted as a function of distance to the isocenter in the LR, AP and CC directions, respectively.
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Figure 1. A CT scan (A) and UTE MR image (B) of the applicator phantom.
Figure 2. Axial slices of T2-TSE images (A1, A3, B1, B3) and UTE images (A2, A4, B2, B4) in two patients (A and B) 
with the applicator in situ.
DISCUSSION
Treatment planning for HDREBT for rectal cancer using the flexible endorectal applicator is currently not 
performed on MRI alone, as the individual channels within the applicator are not visible on MRI images. 
The aim of this study was to test if a UTE sequence can be used to visualize the individual channels within 
the flexible endorectal applicator for HDREBT treatment planning. We have shown that the individual 
channels are visible on UTE images, both in a phantom and in patients. The CNR of the channels and the 
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applicator was higher in patient 2. This may be explained by a partial volume effect due to a difference in 
slice thickness, which was 3.5 mm for patient 1 and 2.5 mm for patient 2.
We observed a systematic shift of the detected marker positions in the UTE image relative to ref_grid
T1_3D
, 
especially in the AP direction. In a clinical application, an anatomical image is used for delineation, while 
the UTE image would be used to visualize the individual channels within the applicator. A rigid registration 
would be performed based on the outline of the applicator and surrounding balloon, negating any 
systematic offsets. After correcting for the systematic shift, the 95th percentile of the residuals is 1.0 mm 
or lower in all directions within a DSV of 550 mm. In addition, within a volume that is typically of interest 
for applicator reconstruction (i.e., a DSV of 300 mm), the 95th percentile of the residuals was 0.3 mm 
(LR), 0.4 mm (AP) and 0.7 mm (CC), which is acceptable for HDREBT treatment planning.
In a UTE sequence, k-space data acquisition starts quickly after the radiofrequency excitation and is 
performed during the ramp up of the gradients [7]. This makes the UTE sequence prone to degraded 
image quality due to eddy currents and unbalanced hardware time delays, that lead to undesired k-space 
trajectory deviations [15]. This could have contributed to the systematic shift we have observed. 
Although for our application it suffices to correct for this shift by using a rigid registration, different 
techniques can be used to measure the actual k-space trajectory to improve the image reconstruction 
[15–17].
Figure 3. Appearance of a single marker of the 3D geometric QA phantom in the axial, sagittal and coronal plane on 
a UTE image and two 3D T
1
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Figure 4. Residuals of the average detected marker positions of the 3D T
1
-weighted images (blue) and residuals of 
detected markers in the UTE image (red) with respect to ref_grid
T1_3D
 in the LR-, AP- and CC-direction as a function 
of distance to isocenter (isoc) in the LR-, AP- and CC-direction, respectively.
68 | Chapter 4
Table 2. Measured residuals of detected marker positions in the UTE image relative to ref_grid
T1_3D
 in the LR, AP and 
CC direction after rigid registration of the detected markers in the UTE image to ref_grid
T1_3D
. 
DSV (mm) Percentile LR (mm) AP (mm) CC (mm) No. of markers
100 5th 0.0 0.0 0.0 11
50th 0.1 0.1 0.1
95th 0.2 0.4 0.7
200 5th 0.0 0.0 0.0 121
50th 0.1 0.1 0.2
95th 0.3 0.4 0.6
300 5th 0.0 0.0 0.0 387
50th 0.1 0.2 0.3
95th 0.3 0.4 0.7
400 5th 0.0 0.0 0.0 862
50th 0.1 0.2 0.3
95th 0.5 0.6 0.8
550 5th 0.0 0.0 0.0 1428
50th 0.2 0.3 0.3
95th 1.0 0.9 0.9
CONCLUSIONS
The endorectal applicator and the individual channels can be adequately visualized using a UTE sequence 
in both a phantom and patients. After a rigid registration to an anatomical image, the geometric fidelity 
of the UTE sequence is within acceptable range. The UTE sequence is therefore suitable for HDREBT 
treatment planning.
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ABSTRACT
Purpose
To evaluate the feasibility of fiducial markers as a surrogate for GTV position in image-guided radiotherapy 
of rectal cancer.
Methods and materials
We analyzed 35 fiducials in 19 rectal cancer patients who received short course radiotherapy or long-
course chemoradiotherapy. A MRI exam was acquired before and after the first week of radiotherapy 
and daily pre- and post-irradiation CBCT scans were acquired in the first week of radiotherapy. Between 





 displacement relative to bony anatomy was determined. Using the CBCT scans, inter- and 
intrafraction fiducial displacement relative to bony anatomy was determined.
Results
The systematic error of the fiducial displacement relative to the COG
GTV
 was 2.8, 2.4 and 4.2 mm 
in the left-right (LR), anterior-posterior (AP) and craniocaudal (CC) direction. Large interfraction 
systematic errors of up to 8.0 mm and random errors up to 4.7 mm were found for COG
GTV
 and fiducial 
displacements relative to bony anatomy, mostly in the AP and CC directions. For tumors located in the 
mid- and upper rectum these errors were up to 9.4 mm (systematic) and 5.6 mm (random) compared to 
4.9 mm and 2.9 mm for tumors in the lower rectum. Systematic and random errors of the intrafraction 
fiducial displacement relative to bony anatomy were ≤2.1 mm in all directions.
Conclusions
Large interfraction errors of the COG
GTV 
and the fiducials relative to bony anatomy were found. Therefore, 
despite the observed fiducial displacement relative to the COG
GTV
, the use of fiducials as a surrogate for 
GTV position reduces the required margins in the AP and CC direction for a GTV boost using image-
guided radiotherapy of rectal cancer. This reduction in margin may be larger in patients with tumors 
located in the mid- and upper rectum compared to the lower rectum.
INTRODUCTION
Neoadjuvant radiotherapy reduces local recurrence rates after surgery in rectal cancer patients [1–4]. 
A pathological complete response is observed in 15-25% of patients after neoadjuvant chemoradiation 
[5,6]. In addition, dose escalation is suggested to result in higher complete response rates, which is 
attractive considering the increased interest in organ preservation [6–10].
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The current clinical practice for setup correction in external-beam radiotherapy of rectal cancer is based 
on bony anatomy using cone beam computed tomography (CBCT) [11]. To ensure proper gross tumor 
volume (GTV) coverage in a GTV boost setting, a planning target volume (PTV) margin of 7-30 mm is 
used to accommodate delineation errors, setup errors and inter- and intrafraction motion of the GTV 
[12–16]. Setup correction based on the GTV instead of bony anatomy may decrease the required PTV 
margins. However, this is challenging due to the limited soft tissue contrast of CBCT [17]. MR-guided 
radiotherapy systems could be used to perform setup correction based on a direct visualization of the 
GTV with superior soft tissue contrast [18]. However, such systems are not widely available yet. Given 
that fiducial markers have been proven useful for setup correction in other tumor locations such as 
pancreas, esophagus and prostate [19–21], fiducials may be useful as a surrogate for GTV position in 
rectal cancer. Several studies have reported on the use of fiducials in the rectum and focus on marker 
visibility and migration [22], fiducial retention and adverse events [23,24] and the use of fiducials to aid 
in the delineation of the target volume [25]. However, none have investigated the potential benefit of 
fiducials for setup correction in radiotherapy of rectal cancer.
In order to use fiducials as a surrogate for the GTV, the position of the fiducials must be representative 
of the position of the GTV. The aim of this study was therefore to evaluate the feasibility of fiducials as a 
surrogate for GTV position in radiotherapy of rectal cancer.
METHODS AND MATERIALS
Patients 
Between July 2015 and September 2016, we included 20 patients with proven rectal adenocarcinoma 
who were scheduled for short-course radiotherapy (SC-RT; 5x5 Gy) or long-course chemoradiotherapy 
(LC-CRT; 25x2 Gy combined with capecitabine 825 mg/m² twice daily on days of radiotherapy) followed 
by total mesorectal excision. Patients were treated in supine position. Before each radiotherapy fraction, 
patients were asked to void their bladder and subsequently drink 300 cc of water to reproduce bladder 
filling. 
Exclusion criteria were contraindication for fiducial insertion (coagulopathy or anticoagulantia that 
could not be stopped), prior pelvic irradiation, pelvic surgery or hip replacement surgery, pregnancy, a 
contraindication for MRI or world health organization performance status 3-4. This study was registered 
at the Dutch Trial Registry (REMARK study, registration no. NL4473) [26].
Fiducials
We used four types of fiducials, inserted in five patients each (Visicoil 0.5x5 mm and Visicoil 0.75x5 
mm [IBA Dosimetry, GmbH, Germany], Cook 0.64x3.4 mm [COOK Medical, Limerick, Ireland] and Gold 
Anchor 0.28x20 mm (unfolded length)[Naslund Medical AB, Sweden]). We endoscopically placed the 
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fiducials in the tumor and mesorectum at least one day before the start of radiotherapy. The fiducial 
insertion strategy is described in Rigter et al. [24].
MRI processing
We performed two multiparametric MRI exams for each patient on a Philips Achieva 1.5T, Philips 
Achieva 3T, Philips Achieva dStream 3T or Philips Ingenia 3T. Details of the scan protocol are listed in 
the supplementary materials. We acquired a first MRI exam up to two weeks before or up to one week 
after the start of radiotherapy and a second MRI exam between one and two weeks after the start of 
radiotherapy. In an earlier study, we evaluated the MRI visibility of the fiducials and we identified 17 
out of 34 fiducials on the first MRI and 9 out of 30 fiducials on the second MRI [27]. The Visicoil 0.75 
and the Gold Anchor were the best visible fiducials on MRI. In addition, a consensus meeting with a 
radiologist (EP) and a resident radiation oncologist (ER) was held to identify more fiducials for this study. 
We delineated the artifacts that the fiducials created on MRI on the tT2-TSE scan with help of the other 
available sequences. The coordinate of the center of gravity (COG) of this delineation represented the 
fiducial position.
The GTV was delineated on the tT2-TSE scan of both MRI exams by one observer (RE) and subsequently 
checked by a radiation oncologist (FP) in Oncentra (Elekta, Veenendaal, the Netherlands). We registered 
the tT2-TSE sequence of the second MRI exam to the tT2-TSE sequence of the first MRI exam using 
Elastix [28] with a rigid transformation based on the bony anatomy of the pelvis and the sacrum. 
We selected both ischial spines and the pubic symphysis as anatomical landmarks on the bony anatomy 
on the MRI exams to assess registration accuracy. The registration accuracy was defined as the mean 
and standard deviation of the distances between a landmark position on the registered second MRI 
exam and the corresponding landmark position on the first MRI exam.
To determine the displacement of the fiducials relative to the GTV, we calculated the displacement for 
each fiducial relative to the center of gravity of the GTV delineation (COG
GTV
) on the second MRI with 
respect to the first MRI. Subsequently, we determined the mean of means (M) by calculating the mean 
displacement over all fiducials and the group systematic error (Σ) by calculating the standard deviation 
over all fiducial displacements [29]. 
To determine the interfraction GTV displacement relative to bony anatomy, we calculated the 
displacement of the COG
GTV
 relative to bony anatomy on the second MRI with respect to the first MRI. 
Subsequently, we determined the mean of means by calculating the mean displacement over all COG
GTV
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To test for differences in displacement between proximal and distal tumors, we calculated the 
interfraction COG
GTV
 displacement relative to bony anatomy on MRI separately for patients with a tumor 
in the mid- and upper rectum (7-16 cm from anal verge) and the lower rectum (0-6 cm from anal verge) 
[30].
CBCT processing
During the first week of radiotherapy, we acquired daily pre- and post-irradiation CBCT scans (Elekta XVI, 
reconstructed slice thickness 1.0 mm, pixel spacing 1.0 mm x 1.0 mm). For the patients that were treated 
with LC-CRT, pre-irradiation CBCT scans were acquired weekly after the first week of radiotherapy.
The first pre-irradiation CBCT scan was used as the reference scan. We registered all subsequent CBCT 
scans to the reference scan using Elastix with a rigid registration based on the bony anatomy of the pelvis 
and the sacrum [28]. The registration accuracy was assessed using the same method as described for 
the MRI exams, with the promontory as an additional anatomical landmark.
We segmented fiducials on the reference and registered CBCT scans by manually selecting a point 
on each fiducial. A box of 12x12x12 mm was automatically created around each selected point and a 
threshold that was well above the image intensities of the surrounding soft tissue was applied to 
segment the fiducial. The coordinate of the COG for each fiducial segmentation was used as the position 
for each fiducial.
The displacement of the COG of all fiducials (COG
FID
) as a result of changes in fiducial configuration was 
calculated as follows. For patients with two or more fiducials in situ, the position of each fiducial relative 
to the COG
FID
 was determined on each pre-irradiation CBCT scan. To assess the resulting displacement 
of the COG
FID
, we calculated the standard deviation of each fiducial position relative to COG
FID
 over 
all pre-irradiation CBCT scans (SD
FID
) and subsequently calculated the standard deviation (SD) of the 
COG
FID
 for each patient with two or more fiducials in situ:
with the squared standard deviation of a fiducial position relative to 
COG
FID
 over all pre-irradiation CBCT scans in the patient and n the number of fiducials in the patient. 
Subsequently, we determined the group random error (σ) by calculating the root-mean-square of all the 
standard deviations of COG
FID
 [29].
To determine the interfraction fiducial displacement relative to bony anatomy, we calculated the 
displacement of each fiducial on each pre-irradiation CBCT scan with respect to the reference scan. 
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To determine the intrafraction fiducial displacement relative to bony anatomy, we calculated the 
displacement of each fiducial on the post-irradiation CBCT scan with respect to the pre-irradiation 
CBCT scan of the same fraction. For each fiducial, we calculated a mean displacement and corresponding 
standard deviation over all fractions for the inter- and intrafraction displacement in the left-right (LR), 
anterior-posterior (AP) and craniocaudal (CC) direction. Subsequently, we calculated for the inter- and 
intrafraction fiducial displacement the mean of means over all fiducials and the group systematic and 
random error by calculating the standard deviation of the mean displacements of all fiducials and the 
root-mean-square of the standard deviation of all fiducials [29].
To test for differences in displacement between proximal and distal tumors, we calculated the 
interfraction fiducial displacement relative to bony anatomy separately for patients with a tumor in the 
mid- and upper rectum (7-16 cm from anal verge) and the lower rectum (0-6 cm from anal verge) [30].
Treatment margins
To determine PTV margins, we quadratically added systematic and random errors of the different 
components to derive the combined errors for the GTV position in three image-guidance scenarios, 
using the Van Herk et al. margin recipe [31]. For setup correction based on bony anatomy, the inter- 
and intrafraction displacement of the GTV relative to the bony anatomy needs to be considered. We 
derived the interfraction displacement relative to bony anatomy in two ways. First from the COG
GTV 
displacement on MRI and second from the fiducial displacements on CBCT. Both were combined with 
the intrafraction fiducial displacement on CBCT to calculate the errors for setup correction based on 
bony anatomy. In a scenario of setup correction based on fiducials, we also need to consider the position 
uncertainty of the GTV relative to the fiducials. Therefore, we combined the fiducial displacement 
relative to the COG
GTV
 with the COG
FID
 displacement as a result of changes in fiducial configuration and 
the intrafraction fiducial displacement relative to bony anatomy on CBCT. In a scenario in which the 
GTV can be visualized directly for setup correction, we only used the errors of the intrafraction fiducial 
displacement relative to bony anatomy.
Statistical analysis
We used SPSS Statistics 23 (IBM Corp. Released 2015. IBM SPSS Statistics for Windows, Version 
23.0. Armonk, NY: IBM Corp.) for statistical analysis. Because of the small sample size in this study, we 
used the non-parametric Mann-Whitney U test to test for differences between the mean and standard 
deviation of the fiducial displacements according to the distance from the anal verge.
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RESULTS
Patients and fiducials
One patient was excluded as all fiducials were inadvertently inserted in the prostate. Therefore, 19 
patients were available for analysis, of whom 8 received SC-RT and 11 received LC-CRT. Patient 
characteristics are shown in Table 1. The fiducial retention in the REMARK study was described earlier 
[32]. A total of 35 fiducials in situ were available for analysis on CBCT, of which 26 fiducials in the tumor 
and 9 in the mesorectum [27]. The consensus meeting resulted in 22 identified fiducials on the first 
MRI and 17 identified fiducials on the second MRI. All 17 fiducials identified on the second MRI were also 
identified on the first MRI. Of those, 14 fiducials were inserted in the tumor and 3 fiducials were inserted 
in the mesorectum. Examples of a GTV delineation and a fiducial on the T2-TSE sequence of both MRI 
exams and a fiducial on two CBCT scans is shown in Figure 1.
Imaging
Median time from the first MRI to the start of radiotherapy was 0 days (range -5 to 12 days). Median time 
between the first and second MRI exam was 7 days (range 4-21 days). For two patients who were treated 
with LC-CRT, the first MRI exam was acquired 2 days (2 fractions) and 5 days (3 fractions) after start of 
radiotherapy. The median delineated GTV volume was 22.8 cc (range 6.9 – 64.6 cc) for the first MRI and 
15.2 cc (range 6.1 – 71.0 cc) for the second MRI. Median difference between the GTV volumes of the first 
and second MRI was -3.0 cc (range -26.5 – 6.4 cc), with a negative difference indicating a smaller volume 
in the second MRI. Fourteen out of nineteen delineated GTV volumes were smaller on the second MRI. 
The MRI registration error was on average 0.0 ± 0.6 mm (LR), 0.2 ± 1.4 mm (AP) and -0.1 ± 1.3 mm (CC).
A total of 219 CBCT scans were acquired in 19 patients (range 2 - 21 per patient), of which 132 pre-
irradiation CBCT scans in 19 patients and 87 post-irradiation CBCT scans in 17 patients. The average 
time between pre- and post-irradiation CBCT scans was 9 ± 1 minutes. The CBCT registration error was 
on average -0.1 ± 0.7 mm (LR), -0.2 ± 0.9 mm (AP) and 0.0 ± 0.8 mm (CC).
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Inter- and intrafraction displacement
The systematic error of the interfraction fiducial displacement relative to the COG
GTV
 was 2.8 mm (LR), 
2.4 mm (AP) and 4.2 mm (CC) as shown in Table 2. The random error of the interfraction displacement 
of the COG
FID
 was <1 mm in all directions. 
The systematic error of the COG
GTV 
 displacement relative to bony anatomy was substantially larger than 
the systematic error of the fiducial displacement relative to bony anatomy on CBCT in the AP (7.2 mm 
vs 4.8 mm) and CC direction (8.0 mm vs 4.6 mm). This was mainly due to two patients who showed a 
large COG
GTV
 displacement on MRI in the AP and CC direction: 15 mm and -20 mm (AP), and -16 mm and 
20 mm (CC). After reviewing the MRI exams, we observed a large difference in the amount of air in the 
rectum which displaced the GTV. In one of these patients also a large difference in bladder filling was 
observed. In the other 17 patients, the group systematic error of the COG
GTV
 displacement relative to 
bony anatomy was 4.1 mm (AP) and 5.6 mm (CC), in line with the fiducial displacement relative to bony 
anatomy on CBCT.
Table 2. Mean of means, systematic error and random error for the different analyses
LR (mm) AP (mm) CC (mm) Available data






M -0.9 0.5 -0.2 MRI scans 26
∑ 2.8 2.4 4.2 Fiducials 17
σ - - - Patients 13
Interfraction displacement of 
COG
FID
 as a result of changes in 
fiducial configuration (CBCT)
M - - - CBCT scans 76
∑ - - - Fiducials 27
σ 0.6 0.9 0.9 Patients 11
Interfraction displacement  
w.r.t. bony anatomy




M -0.2 0.5 -1.2 MRI scans 38
∑ 2.8 7.2 8.0 Patients 19
σ - - -
Interfraction displacement of 
fiducials (CBCT)
M 0.4 -2.7 1.2 CBCT scans 132
∑ 3.6 4.8 4.6 Fiducials 35
σ 2.7 4.2 4.7 Patients 19
Intrafraction displacement  
w.r.t. bony anatomy
Intrafraction displacement of 
fiducials (CBCT)
M -0.1 -0.5 1.1 CBCT scans 87
∑ 0.8 1.4 1.6 Fiducials 32
σ 1.4 1.7 2.1 Patients 17
LR = left-right, AP = anterior-posterior, CC = craniocaudal, M = mean of means, ∑ = systematic error, σ = random error
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Figure 1. Examples of a GTV delineation and a fiducial on the T2-TSE sequence of both MRI exams (A and B) and the 
same fiducial on two pre-irradiation CBCT scans (C and D) for patient 19.
For the interfraction COG
GTV
 displacement relative to bony anatomy, the systematic error was 3.0 mm 
(LR), 8.7 mm (AP) and 9.4 mm (CC) for patients with a tumor in the mid- and upper rectum, while it was 
1.3 mm (LR), 4.7 mm (AP) and 4.9 mm (CC) for patients with a tumor in the lower rectum. Similarly, for 
the interfraction fiducial displacement relative to bony anatomy on CBCT, systematic and random errors 
were 3.8 and 3.4 mm (LR), 6.1 and 5.1 mm (AP) and 5.5 and 5.6 mm (CC) for the mid- and upper group 
and 3.1 and 1.1 mm (LR), 1.6 and 2.3 mm (AP) and 2.8 and 2.9 mm (CC) for the lower rectum group. The 
standard deviation of the interfraction fiducial displacements relative to bony anatomy was significantly 
higher for patients with a tumor in the mid- and upper rectum compared to patients with a tumor in the 
lower rectum in the LR (p<0.01), AP (p=0.03) and CC (p=0.04) direction. An overview of the inter- and 
intrafraction fiducial displacements relative to bony anatomy split according to tumor location is shown 
in Figure 2 and Figure 3.
Systematic and random errors of the intrafraction fiducial displacement relative to bony anatomy were 
≤2.1 mm in all directions.
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Setup correction scenarios
For setup correction based on bony anatomy, the estimated margins were 8.3 mm (LR), 19.5 mm (AP) 
and 21.9 mm (CC) using the COG
GTV 
displacement relative to bony anatomy, and 11.3 mm (LR), 15.7 mm 
(AP) and 15.8 mm (CC) using the fiducial displacement relative to bony anatomy
 
(Table 3). For setup 
correction based on fiducials, a reduction to 8.3 mm (LR and AP) and 12.8 mm (CC) was observed. Setup 
correction based on a direct visualization of the GTV would further reduce required margins to 3.0 mm 
(LR), 4.7 mm (AP) and 5.5 mm (CC).
Figure 2. Boxplots of the interfraction fiducial displacements relative to bony anatomy on CBCT in the LR, AP and CC 
direction, split according to tumor location.
Figure 3. Boxplots of the intrafraction fiducial displacements relative to bony anatomy on CBCT in the LR, AP and CC 
direction, split according to tumor location.
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Table 3. Systematic error, random error and corresponding margin for different setup correction scenarios
LR (mm) AP (mm) CC (mm)
Setup correction based on bony anatomy (COG
GTV
 MRI data) Σ 2.9 7.3 8.2
σ 1.4 1.7 2.1
Margin 8.3 19.5 21.9
Setup correction based on bony anatomy (fiducial CBCT data) Σ 3.7 5.0 4.9
σ 3.0 4.5 5.1
Margin 11.3 15.7 15.8
Setup correction based on fiducials Σ 2.9 2.8 4.5
σ 1.5 1.9 2.3
Margin 8.3 8.3 12.8
Setup correction based on GTV Σ 0.8 1.4 1.6
σ 1.4 1.7 2.1
Margin 3.0 4.7 5.5
LR = left-right, AP = anterior-posterior, CC = craniocaudal, Σ = systematic error, σ = random error
DISCUSSION
The aim of this study was to evaluate the feasibility of fiducials as a surrogate for GTV position in rectal 
cancer. Despite fiducial displacement relative to the COG
GTV
, an advantage for fiducial setup correction 
was observed in the AP and CC direction compared to bony anatomy setup correction. Consequently, 
the use of fiducials in a GTV boost setting allows for more precise irradiation of the GTV and sparing 
of organs at risk. More organ motion of the proximal rectum compared to the distal rectum is reported 
[33–35]. Although only a small number of patients were included in our study, a similar difference was 
observed. This suggests that the advantage of setup correction based on fiducials may be larger in 
patients with a proximal tumor.
The interfraction systematic error of the COG
GTV
 relative to bony anatomy, as based on MRI, was 
substantially larger than the systematic and random errors of the fiducial displacements on CBCT. 
This is mainly due to large displacement of the COG
GTV
 in two patients on MRI and may be explained 
by the absence of patient preparation before the MRI exams. For the calculation of the displacement 
of the COG
FID
 as a result of changes in fiducial configuration, the COG
FID
 was used as a reference point, 
assuming that all fiducials contributed equally to changes in fiducial configuration.
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There is an inherent inaccuracy in determining exact fiducial locations on MRI, for instance due to the 
asymmetrical artifacts of the fiducials [36]. With help of the other available sequences, we delineated 
the fiducials on the tT2-TSE scan as it had the smallest artifacts [27]. Therefore, we believe that 
the inaccuracy in selecting the exact fiducial location has a minor effect on the observed fiducial 
displacements on MRI.
In the last two decades, organ motion in rectal cancer patients has been actively investigated and 
most studies focus on the movement of the clinical target volume (CTV) relative to bony anatomy 
[11,33,34,37–39]. Only a few papers have investigated the position variability of the GTV to determine 
the required margins for a GTV boost. Kleijnen et al. studied the motion of the rectum and GTV based 
on repeated MRI data [40–42]. They evaluated the intra- and interfraction displacement of the GTV 
relative to bony anatomy on time intervals of 1 minute, 9.5 minutes, 18 minutes and 1-4 days using daily 
MRI exams in 16 patients. They report a required margin of around 8 mm in all directions for both the 9.5 
minute and 1-4 days timepoints [33]. However, a direct comparison is difficult since they used a different 
method to calculate the displacements and corresponding margins and they did not report the tumor 
location for each patient.
Furthermore, Kleijnen et al. report that although setup errors based on the rectal wall were slightly 
reduced compared to bony anatomy, a similar PTV margin was found. More importantly, the rectal wall 
could not be used as a surrogate for the GTV position, because displacement of the rectal wall and 
the GTV along the direction of the rectal wall will not be detected due to the absence of anatomical 
landmarks on the rectal wall [41]. They conclude that in order to further reduce uncertainties in a GTV 
boost setting, direct or indirect online tumor visualization is needed. In our study, we have shown that 
fiducials as an indirect visualization of the GTV reduces uncertainties. However, an uncertainty of the 
GTV position relative to the fiducials remains. 
The suggested margins for setup correction based on bony anatomy as reported by Kleijnen et al. [42] 
are lower than those in our study, especially in the AP direction. However, a direct comparison is difficult 
since they did not report on the tumor location and intrafraction displacement of the tumor. Brierley et al. 
assessed the interfraction displacement of the rectum, mesorectum and GTV relative to bony anatomy 
[35]. They found that the GTV displacement was greatest in the CC direction, which is confirmed by the 
results in our study.
A limitation of the use of fiducials might be the low retention rate. In our study, a total of 64 fiducials 
were inserted, of which 35 fiducials were still in situ at the end of radiotherapy [24]. Furthermore, 
the insertion of fiducials is an invasive procedure. Previous studies on fiducial insertion in the rectum 
report no serious adverse events [22,24,25]. In one study, a small amount of bleeding that resolved 
spontaneously was reported in one out of 54 patients [23].
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A limitation of this study is the small number of patients. Therefore, the determined margins and the 
observed difference between proximal and distal tumors would need confirmation in a larger study. As 
only 3 fiducials in the mesorectum were identified on both MRI exams, no conclusions can be drawn 
about fiducial displacement with respect to the tumor between fiducials implanted in the tumor and the 
mesorectum. Furthermore, we evaluated the displacement of the fiducials relative to the GTV only for the 
first week of radiotherapy. If fiducials would be used for the full duration of a long-course radiotherapy 
schedule, the displacement of the fiducials relative to the GTV should be investigated for all five weeks. 
Because of logistical reasons, the time between the MRI exams differed between patients. However, 
the difference is mainly due to the time range of the first MRI exam relative to the start of radiotherapy. 
Finally, the estimated margins presented in this paper are based on the position of the fiducials and GTV 
and do not include other remaining errors involved in the treatment process.
CONCLUSIONS
The results of this study show that despite the observed fiducial displacement relative to the GTV, the 
use of fiducials as a surrogate for GTV position reduces required margins in the AP and CC direction for 
a GTV boost using image-guided radiotherapy of rectal cancer. The reduction of required margins may 
be higher in patients with a proximal compared to a distal tumor. However, this needs to be confirmed 
in a larger study.
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ABSTRACT
Background
The STAR-TReC trial is an international multi-center, randomized, phase II study assessing the feasibility 
of short-course radiotherapy or long-course chemoradiotherapy as an alternative to total mesorectal 
excision surgery. A new target volume is used for both (chemo)radiotherapy arms which includes only 
the mesorectum. The treatment planning QA revealed substantial variation in dose to organs at risk 
(OAR) between centers. Therefore, the aim of this study was to determine the treatment plan variability 
in terms of dose to OAR and assess the effect of a national study group meeting on the quality and 
variability of treatment plans for mesorectum-only planning for rectal cancer.
Methods and materials
Eight centers produced 25x2 Gy treatment plans for five cases. The OAR were the bowel cavity, bladder 
and femoral heads. A study group meeting for the participating centers was organized to discuss the 
planning results. At the meeting, the values of the treatment plan DVH parameters were distributed 
among centers so that results could be compared. Subsequently, the centers were invited to perform 
replanning if they considered this to be necessary.
Results
All treatment plans, both initial planning and replanning, fulfilled the target constraints. Dose to OAR 
varied considerably for the initial planning, especially for dose levels below 20 Gy, indicating that there 
was room for trade-offs between the defined OAR. Five centers performed replanning for all cases. One 
center did not perform replanning at all and two centers performed replanning on two and three cases, 
respectively. On average, replanning reduced the bowel cavity V20Gy by 12.6%, bowel cavity V10Gy by 
22.0%, bladder V35Gy by 14.7% and bladder V10Gy by 10.8%. In 26/30 replanned cases the V10Gy of 
both the bowel cavity and bladder was lower, indicating an overall lower dose to these OAR instead of 
a different trade-off. In addition, the bowel cavity V10Gy and V20Gy showed more similarity between 
centers.
Conclusions
Dose to OAR varied considerably between centers, especially for dose levels below 20 Gy. The study 
group meeting and the distribution of the initial planning results among centers resulted in lower dose to 
the defined OAR and reduced variability between centers after replanning.
BACKGROUND
Only 2% of the patients with early stage rectal cancer treated with total mesorectal excision (TME) 
surgery experience local failure and 12% develop a distant failure [1–3]. However, TME surgery can 
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result in significant morbidity and mortality [4–6]. For a distal tumor, approximately 40% of patients 
require a permanent stoma. Complications of TME surgery include anastomotic leaks, urinary and 
fecal incontinence and sexual dysfunction. Therefore, research for this early stage rectal cancer patient 
group has focused on alternative strategies, such as limited resections and active surveillance of good 
responders after chemoradiotherapy [7–10]. 
The STAR-TReC trial is an international multi-center, randomized, phase II study assessing the feasibility 
of short-course radiotherapy (SC-RT) or long-course chemoradiotherapy (LC-CRT) with subsequent 
two-stage response assessment as an alternative to TME surgery. Patients are randomized between; a) 
TME b) organ preservation utilizing LC-CRT and c) organ preservation utilizing SC-RT (ClinicalTrials.gov 
Identifier: NCT02945566) [11]. A novel target volume is used which includes only the mesorectum [12]. 
Before patient accrual, each center had to go through a radiotherapy quality assurance (QA) program led 
by national radiotherapy trial teams, including a delineation and a treatment planning case. The results 
for the treatment planning showed substantial variation in dose to organs at risk (OAR), suggesting that 
different trade-offs were made in each center. Therefore, the Dutch radiotherapy trial team (FP, CM 
and EK) decided to extend the QA program with four additional planning cases and organized a study 
group meeting for the Dutch centers in the STAR-TReC trial. The aim of this study was to determine 
the variability in treatment plans in terms of dose to OAR and to determine the effect of a study group 
meeting on the quality and variability of treatment plans for mesorectum-only planning for rectal cancer.
METHODS AND MATERIALS
Participating centers and patients
Eight centers participated in this study. We selected 5 cases, including the treatment planning case of 
the radiotherapy QA program, according to the STAR-TReC inclusion criteria with a small (< 4 cm) T1-
3bN0M0 tumor without involvement of the mesorectal fascia or extra-mural vascular invasion.
Target volume and OAR
The STAR-TReC trial utilizes an adapted definition of the clinical target volume (CTV) that only includes 
the mesorectum from two centimeters below the tumor up to the S2-3 interspace level. This is a smaller 
CTV compared to the current standard for radiotherapy of rectal cancer and it is specially tailored for 
early stage disease, with the goal of organ preservation. The development of this new mesorectal CTV 
definition was described in Peters et al. [12]. The planning target volume (PTV) was defined as the CTV 
plus a margin of 15 mm in the anterior direction and 10 mm in the posterior, lateral and craniocaudal 
directions. The defined OAR were the bowel cavity, bladder and femoral heads. The bowel cavity 
was delineated using adapted RTOG guidelines, including abdominal contents and excluding major 
vasculature, muscles and bones, other pelvic organs (e.g. bladder, prostate, vagina, uterus) and the CTV. 
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The bowel cavity volume was delineated up to 2 cm above the superior extent of the PTV and inferiorly 
where small bowel or colon was visible. The whole bladder was delineated including the bladder wall. 
The femoral heads were delineated to the most inferior extent of the lesser trochanter. The CTV and the 
OAR of all 5 cases were delineated by one observer (FP) on the planning CT scan.
Treatment planning
We sent the planning CT scans with the corresponding delineations to each participating center, so that 
each center performed treatment planning based on the same delineations. They were asked to produce 
LC-CRT treatment plans of 25x2 Gy according to the STAR-TReC study protocol. The participating 
centers were experienced centers in the treatment of rectal cancer patients. Different planning systems 
and treatment delivery techniques were used among the centers, as shown in Table 1. Treatment plans 
were produced by radiotherapy technologists with 0 – 20 years of treatment planning experience. 
Participating centers used the same criteria regarding delivery efficiency as they would use in clinical 
practice, the constraints regarding delivery efficiency are shown in Table 1.
The target volume constraints were defined according to the ICRU 83 criteria, focusing on full coverage 
of the target volume with CTV V95% = 100%, PTV V95% ≥ 99%, PTV V90% = 100%, PTV V105% ≤ 
1% and 98% ≤ PTV D50% ≤ 102%. There is lack of data on the association of dose to bowel, bladder 
and femoral heads and the risk of late complications for dose levels up to 50 Gy. Therefore, the study 
protocol had no mandated OAR constraints but specified optimization objectives for the OAR adapted 
from Appelt et al. [13]: bowel cavity V20Gy < 190 cc, V30Gy < 130 cc, V45Gy < 100 cc, bladder V35Gy 
< 22%, V50Gy < 7% and femoral head left and right V25Gy < 14%.
Study group meeting
After all centers had completed the treatment planning on all cases, we organized a study group 
meeting to discuss the planning results. A radiation-oncologist, a medical physicist and a radiotherapy 
technologist with rectal cancer expertise of each participating center were invited for this meeting. 
During the meeting, we visualized the values of the DVH parameters of all treatment plans and the dose 
distributions of specific cases to discuss the differences.
We distributed the values of the DVH parameters of all treatment plans among all centers so that results 
could be compared. Subsequently, we invited the participating centers to perform replanning if they 
considered this to be necessary.
Treatment plan comparison
Each participating center returned for each case the DVH parameters and the dose distribution of the 
initial planning and replanning in DICOM format. To avoid differences in DVH parameters due to different 
treatment planning systems, we calculated the values of the DVH parameters using an independent 
DVH calculation on the submitted dose distributions. We assessed the accuracy of our independent 
Radiotherapy QA for mesorectum treatment planning | 93
DVH calculation algorithm using a gamma-analysis between dose volume histograms calculated by the 
algorithm and dose volume histograms calculated by our treatment planning system for a dataset of eight 
patients with varying target volumes and organs at risk. We used a tolerance of 0.1 Gy and 1% volume. 
In addition, we compared the DVH parameters calculated by the algorithm with the DVH parameters 
submitted by the participating centers, which were calculated by their treatment planning systems.
To determine the effect of the study group meeting on the dose to OAR, we compared the values of the 
DVH parameters of the replanned cases to the initial plans. In addition to the DVH parameters of the 
OAR optimization objectives, we selected additional DVH parameters for a more detailed evaluation 
of the differences in low dose levels. The additional parameters included the V5Gy, V10Gy, and V15Gy 
for the bowel cavity as well as the bladder. No constraints or objectives were imposed on the additional 
DVH parameters. 
To investigate the total volume of the V10Gy and V25Gy, we added a volume that included the patient 
contour of the planning CT scan. In addition, we added a volume that included the patient contour of 
the planning CT scan but excluded the PTV, bowel cavity, bladder and femoral heads to investigate if the 
dose to other normal tissue was increased while sparing the defined OAR. This volume is called “Non-
defined OAR”.
For the cases for which no replanning was performed, we reported the values of the DVH parameters of 
the initial planning of those centers as the result of the replanning.
Statistical analysis
We used SPSS Statistics 23 (IBM Corp. Released 2015. IBM SPSS Statistics for Windows, Version 23.0. 
Armonk, NY: IBM Corp.) for statistical analysis. A paired samples T-test was used to test for differences 
in the values of the DVH parameters between the initial planning and replanning. The significance 
threshold was set at p < 0.002, adjusted for multiple testing using the Bonferroni correction.
RESULTS
DVH calculation algorithm
The gamma passing rate of the dose volume histograms calculated by the independent DVH calculation 
algorithm was 99.99 ± 0.03%. On average, the relative difference between the DVH parameters 
calculated by the independent DVH calculation algorithm and the DVH parameters submitted by the 
centers was -0.5 ± 0.2%. 
94 | Chapter 6
Initial planning
All plans satisfied the target volume constraints. Large differences in dose to OAR were observed, 
especially in the dose levels below 20 Gy, as shown in Figure 1. The differences were discussed at the 
study group meeting, where it was concluded that the variation was mostly due to differences in local 
practice and lack of evidence for OAR constraints. As there is insufficient evidence to support prioritizing 
the sparing of OAR at these low dose levels, the prioritization was left to the center’s preference.
Replanning
Five centers performed replanning for all cases. Center 2 performed replanning on two cases, center 
3 did not perform replanning at all and center 5 performed replanning on three cases. Center 1 used 
Pinnacle AutoPlanning for the replanning. All other centers performed replanning using the same 
treatment technique as the initial planning, as described in Table 1. All 30 replanned cases fulfilled the 
target volume constraints. For all cases, replanning resulted on average in a lower dose to the defined 
OAR (Table 2). The bowel cavity V5Gy, V10Gy, V15Gy, V20Gy, V30Gy and V45Gy and the bladder 
V10Gy, V15Gy and V35Gy were significantly lower in the replanning for all cases (p<0.001). On average, 
replanning reduced the bowel cavity V20Gy by 12.6%, the bowel cavity V10Gy by 22.0%, the bladder 
V35Gy by 14.7% and the bladder V10Gy by 10.8%.
Figure 2 shows for each case the bowel cavity V10Gy and bladder V10Gy for the initial planning and the 
replanning of all cases. All vectors (except three; center 1 for case 1, center 8 for case 4 and center 4 for 
case 5) show that both the bowel cavity V10Gy and the bladder V10Gy was lower after replanning. This 
reduction was at the expense of the V10Gy in the non-defined OAR, which on average is higher after 
replanning for all cases, except case 3. The bowel cavity V15Gy and bladder V15Gy were lower in 25/30 
replanned cases and the bowel cavity V30Gy and bladder V35Gy were lower in 23/30 replanned cases. 
The bowel cavity V10Gy and V20Gy showed more homogeneity between centers after replanning, as 
depicted in Figure 1.
Radiotherapy QA for mesorectum treatment planning | 95
Figure 1. Planning results for the initial planning (blue) and replanning (orange) for each case. The red lines indicate 
the OAR optimization objective.
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Figure 2. Vector representation for the initial planning and replanning for the bowel cavity V10Gy and the bladder 
V10Gy for all cases. A vector originates in the values of the DVH parameters of the initial planning and ends in the 
values of the replanning. The numbers 1 through 8 in the figure legends represent the centers. A plotted point 
indicates that the corresponding center did not perform replanning.
An example of the initial planning and replanning for one case is shown separately for all centers in Figure 
3. For the same case, the difference in dose distribution between the initial planning and replanning is 
shown for center 4 and 6 in Figure 4. For center 4, the replanning reduced the dose deposition laterally, 
as shown on the axial images, while the V10Gy isodose is expanded into the pubic bone, as shown on the 
sagittal images. For center 6, replanning reduced the bowel cavity V10Gy and bladder V10Gy while the 
dose deposition is increased laterally.
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Figure 3. Planning results for the initial planning (blue) and replanning (orange) of case 1. The red lines indicate the 
OAR optimization objective.
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Figure 4. Dose distributions for the initial planning and replanning of case 1 for center 4 and center 6.
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DISCUSSION
The aim of this study was to determine the variability in treatment plans in terms of dose to OAR and 
to determine the effect of a study group meeting on the quality and variability of treatment plans using 
a novel target volume for rectal cancer. We have shown that a large variability in dose to OAR occurred 
while the plans of all centers fulfilled the target constraints. After the study group meeting, replanning 
resulted in improved treatment plan quality due to lower doses to the defined OAR and smaller 
differences in dose to OAR between centers.
Optimization objectives for the dose to OAR in the STAR-TReC trial were provided only for dose levels 
above 20 Gy, which left room for variation in the distribution of the lower dose levels. As a result, 
radiation-oncologists made different choices regarding the distribution of these lower dose levels or 
these levels were not taken into account at all during the optimization. 
It is not expected that the observed variations in dose to OAR have an impact on the trial hypothesis. 
However, the observed variations in low dose to the OAR may have an impact on toxicity. Therefore, 
optimization objectives might be added for the lower dose levels in the upcoming phase III study of the 
STAR-TReC trial in order to try to reach more consistent and possibly better treatment plans among 
centers and to prevent unnecessary large volumes of low dose to the OAR. To determine adequate dose 
volume constraints and prioritization for the OAR in the future, data will be gathered for correlation 
between dose to OAR and risk of complications within the STAR-TReC trial.
Evaluating a plan on dose volume constraints or objectives alone may not be a good indicator of plan 
quality, as some patients may have a favorable anatomy and the achieved parameters may not be the 
lowest possible organ dose volumes. On the other hand, in unfavorable patients, dose may not fulfill 
planning criteria or objectives while it is still the most optimal plan for that patient. In our study, this 
can be observed in Figure 1, where for case 4 the bowel cavity V20Gy approaches the objective for all 
centers. However, for the other patients the bowel cavity V20Gy is substantially lower than the objective. 
This shows that careful selection of a benchmark case for trial QA is important and raises the question 
whether one case is sufficient. Multiple cases enable the evaluation of different patient anatomies with 
corresponding degrees of possible OAR sparing.
To determine whether the dose to the defined OAR can be lowered further is difficult, even for 
experienced treatment planners. Plan quality is therefore dependent on planning time, experience of the 
treatment planner and the degree to which the treatment plan is being critically reviewed. The treatment 
plans in this study were made and reviewed extensively by expert planners and radiation-oncologists. 
These treatment plans may therefore not reflect treatment plans produced in clinical practice, as less 
detailed feedback or discussion of treatment plans is possible and plans may therefore be suboptimal. 
Automated treatment planning techniques, for example knowledge-based treatment planning, protocol-
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based automatic iterative optimization or multicriteria optimization, could be used to determine whether 
a treatment plan can be further optimized [14].
Other studies describing trial QA report on the identification of delineation and/or dosimetric 
violations and that participating centers receive individual feedback regarding those violations [15–17]. 
Subsequently, the violations were resolved and treatment plan quality was improved. In our study, 
however, all target constraints and OAR objectives were fulfilled and the question was how to handle the 
variations in dose distribution for the OAR for which no guidelines were yet available. The study group 
meeting has enabled us to discuss the planning results and the considerations regarding dose distribution 
to defined and non-defined OAR face-to-face, by doing so learning from each other. Furthermore, sharing 
the planning results of the initial planning of all centers enabled centers to compare their results and 
helped them decide whether further optimization of the treatment plan was possible and desired for 
each case. Consequently, replanning led to improved plan quality as lower doses to defined OAR were 
observed while maintaining target volume constraints. Importantly, although no consensus guidelines 
were made on how to handle the variations in dose to OAR, the variation of dose levels below 20 Gy was 
reduced after replanning.
CONCLUSIONS
In the STAR-TReC trial, no constraints or objectives are defined for the OAR for lower dose levels since 
there is no clinical evidence to base constraints on. As a result, in this treatment planning study the dose 
to OAR varied considerably between centers, especially for dose levels below 20 Gy. After the study 
group meeting, treatment plan quality was improved as replanning resulted in lower dose to the defined 
OAR and reduced variability between centers. Therefore, for a novel target volume, we recommend to 
include more than one QA case and to share all planning results with participating centers, possibly at 
a study group meeting, to allow them to compare results and decide whether further optimization is 
possible.
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GENERAL DISCUSSION
The studies described in this thesis focus on the reduction of treatment-related uncertainties in image-
guided high-dose-rate endorectal brachytherapy (HDREBT) and external beam radiotherapy (EBRT) for 
rectal cancer patients. Currently, the standard of care for rectal cancer patients consists of a surgical 
resection. Depending on disease stage, neoadjuvant (chemo)radiotherapy is given in order to reduce 
local recurrence rates. After standard chemoradiotherapy, 10-20% of patients develop a complete 
response. In these patients, a ‘watch and wait’ approach in which surgery is omitted seems safe. Dose 
response analyses suggest that escalating the dose to the gross tumor volume (GTV) leads to higher 
response rates. Various dose escalation techniques have been described in literature, including contact 
therapy, HDREBT and EBRT. For a dose escalation technique to be successful, it needs to lead to higher 
complete response rates in combination with limited acute and late toxicity. Therefore, the dose to 
healthy tissue should be as small as possible. In addition, if a boost dose can be delivered with higher 
accuracy, the dose to the GTV could be higher with similar dose to healthy tissue. Although the optimal 
treatment technique for dose escalation has not yet been determined, the work described in this thesis 
can be used to enhance the accuracy and decrease treatment related uncertainties related to a boost 
dose.
For HDREBT, most studies focus on oncological outcome and treatment-related toxicity. Although 
literature describes an adaptive approach using a treatment planning CT at each fraction, the dosimetric 
benefit of such an approach had not been investigated. Furthermore, the preferred image modality for 
target volume definition and treatment planning is MRI due to its superior soft tissue contrast. To realize 
a HDREBT workflow including MRI, a MRI-compatible fiducial marker was required that is visible on MRI 
imaging. Therefore, we have evaluated the visibility of four types of gold fiducial markers on MRI. Finally, 
the individual channels of the applicator are not visible on currently used anatomical MRI sequences. 
To be able to perform treatment planning on MRI, a method was needed to visualize the individual 
channels of the applicator on MRI. We have proposed a MRI sequence utilizing ultrashort echo times for 
visualization of the individual channels within the applicator.
With increased interest for organ preservation, improvements aimed at EBRT boost delivery are timely. 
Although some studies have evaluated the displacement of the GTV with respect to bony anatomy, most 
of them were based on CT and/or CBCT with inherent limited soft tissue contrast for GTV visualization. 
As a result, a wide range of PTV margins of 7-30 mm is described in literature. In addition, fiducial 
markers could be used as a surrogate for the GTV in order to perform setup correction based on fiducials 
instead of bony anatomy. However, data on the stability of fiducials relative to the GTV was lacking. 
Therefore, we have derived GTV displacement relative to bony anatomy using fiducials and provided 
data on the uncertainty of the GTV-fiducial spatial relationship. Together with the evaluation of the MRI 
visibility of four fiducial types, this thesis provides a basis for further research and subsequent clinical 
implementation of an EBRT GTV boost strategy using fiducial markers.
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To facilitate organ preservation and avoid TME surgery in early stage rectal cancer patients, (chemo)-
radiotherapy has to be given to control the tumor. The risk of pelvic lymph node involvement or distal 
mesorectal nodal involvement is low in this group of patients. Therefore, the typically large target volume 
may not be needed in this group of patients, and restricting the target volume to the peritumoral region 
of the primary tumor and mesorectum seems reasonable. In the STAR-TReC trial, a novel target volume 
is used which includes only the mesorectum [1]. Mesorectum only planning is intended for early stage 
rectal cancer with the aim of reducing the clinical target volume (CTV) and thereby reducing dose to the 
healthy tissue while maintaining local control. By showing the impact of a national study group meeting 
on the variability and quality of treatment plans for a novel target volume, we provide a basis for the 
realization of a more homogeneous treatment, potentially improving the quality of clinical trials on 
treatment outcome and toxicity.
High-dose-rate endorectal brachytherapy
Repeat imaging
The HDREBT procedure as described in literature uses a planning CT scan at each fraction and 
endoluminal clips to indicate the tumor position. Position verification prior to irradiation is performed 
with an X-ray, using the endoluminal clips and radiopaque markers inserted in the channels of the 
applicator. Although literature describes a transition from using a single-planning CT for all fractions to 
using a planning CT at each fraction, the difference in terms of target coverage and dose to organs at 
risk had not been evaluated [2–5]. In Chapter 2, we have shown that use of a single planning CT for all 
fractions can result in insufficient target coverage. The most important cause of limited target coverage 
was the presence of air and/or faeces between the applicator and the target volume. Air and/or faeces 
cannot be accurately assessed on the X-ray images used for position verification. Therefore, CT imaging 
at each fraction should be the minimal standard in HDREBT for rectal cancer.
Fiducial markers
Because of the limited soft tissue contrast of CT imaging, ideally a MRI should be used to define the 
target volume. However, the endoluminal clips create large artifacts on MRI, which limits target volume 
visibility. Therefore, an alternative marker allowing target volume visibility on MRI was needed. In 
addition, the alternative marker should be visible on MRI to determine the spatial relationship between 
the target volume and the fiducial marker. To determine a suitable alternative fiducial marker, we have 
evaluated the MRI visibility of four different MR-compatible gold fiducials in Chapter 3. The results of 
the study show that the Visicoil 0.75 and the Gold Anchor were the best visible fiducials on MRI and that 
a corresponding (CB)CT scan is required to provide an estimation of the fiducial localization on MRI. 
Although those fiducials were the best visible in the study, it can be argued whether the use of fiducials 
is clinically feasible, given the limited retention and visibility rate observed in Chapter 3. For future use 
of fiducial markers in the rectum, it is expected that the fiducial retention rate and visibility will improve 
for several reasons. First, the retention rate of fiducials in this study was better for fiducials that were 
inserted in the mesorectum, compared to fiducials inserted in the tumor, as shown by Rigter et al. [6]. 
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Second, the use of a T1 3D sequence with prolonged echo time will increase the size of the artifacts that 
the fiducials create on MRI, which may enhance the fiducial visibility. We therefore recommend to insert 
fiducials in the mesorectum, in proximity of the tumor and to include a T1 3D sequence with prolonged 
echo time of at least 5 ms. Third, in brachytherapy, the planning CT and MRI are acquired with applicator 
in situ. This leads to a more similar anatomy between the CT and MRI, thereby increasing the accuracy of 
initial localization of fiducial markers on MRI.
Although the visibility of fiducials is expected to increase with a T1 3D sequence with prolonged echo 
time, manual fiducial identification on MRI remains a challenging and time-consuming procedure. In 
addition, fiducial marker appearance on MRI depends on sequence parameters and fiducial orientation 
with respect to the magnetic field [7]. Automatic fiducial detection could aid in the identification of 
fiducials and possibly eliminate the need for a corresponding (CB)CT. Multiple studies report on 
automatic fiducial detection on MRI in the prostate, with fiducial detection rates of 94-96% [8–10]. 
Since none report a marker detection rate of 100%, implementation of such a method would have to be 
in a semi-automatic workflow with an initial automatic fiducial detection on MRI with possible manual 
corrections. In addition, the proposed automatic fiducial detection methods would first have to be 
validated for the application in rectal cancer patients.
Given the increased interest in organ preservation strategies for rectal cancer patients, MRI will be 
increasingly used to determine whether a complete response has been reached. Among other sequences, 
a DWI sequence is used to assess tumor response. Since this sequence is sensitive to distortions in 
the magnetic field, fiducial markers that are placed (too) close to the tumor may hamper response 
assessment. As an alternative, a liquid marker that forms a semisolid gel after injection may be used 
[11,12]. These liquid markers are visible on MRI as a signal void due to the absence of water protons. This 
is different compared to gold fiducial markers, which cause signal voids due to absence of water protons 
and due to their alteration of the static magnetic field. Currently, only one study has evaluated the use of 
these liquid markers in rectal cancer [13], with positional stability as primary outcome. Preliminary results 
have been published in an abstract, in which the authors report that after 5 weeks of chemoradiotherapy, 
96% of 74 liquid markers were still in situ and available for analysis. Marker pair distances, as a measure 
for marker stability, showed stable or negative slope of fits during chemoradiation. It was concluded that 
the liquid marker was feasible to act as a tumor location surrogate. However, stability with respect to the 
GTV was not reported in the abstract.
HDREBT MRI-only workflow
As the individual channels within the applicator are not visible on the currently used MRI sequences, 
delineation of the target volume and organs at risk, applicator reconstruction and treatment planning 
are still performed on CT. Image registration of the CT and MRI with applicator in situ is performed to aid 
in the target volume definition. A further improvement in HDREBT treatment planning would be a MRI-
only workflow, in which the delineation of the target volume and organs at risk, applicator reconstruction 
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and treatment planning are all performed on MRI. This would eliminate any image registration errors 
between MRI and CT due to possible changes in applicator position. In addition, it would save time and 
increase patient comfort as the patient does not have to be transferred between CT and MRI. A MRI-only 
workflow can be realized if the fiducials can be identified on MRI without corresponding (CB)CT and if 
the individual channels within the applicator can be visualized. In the previous paragraph, improvements 
have been suggested to facilitate MRI fiducial identification without corresponding (CB)CT, including 
a T1 3D sequence with prolonged echo time and the use of automatic fiducial detection methods. In 
Chapter 4, we have proposed a MRI sequence utilizing an ultrashort echo time to visualize the applicator 
and the individual channels within it. We have shown that the applicator and the individual channels can 
be visualized, both in a phantom and in patients. By performing a rigid registration with an anatomical 
sequence, geometric fidelity was within acceptable range. Therefore, applicator reconstruction, 
delineation of target volume and organs at risk, and treatment planning can all be performed on MRI. 
However, before clinical implementation of such a workflow, the geometrical fidelity of all MRI sequences 
that are going to be used for treatment planning should be verified.
A next step in the HDREBT workflow would be to irradiate the patient while the patient is lying on the 
MRI scan table. This would eliminate the transfer of the patient between the MRI table and the treatment 
table, thereby reducing the chance of changes in applicator position between the planning MRI and the 
time of irradiation. In addition, fiducial markers would no longer be needed as both the target volume 
and the applicator can be visualized using MRI. Irradiation of the patient while the patient is lying in the 
MR bore would however require a MRI-compatible afterloader. The feasibility of such a procedure has 
been demonstrated using a prototype MRI-compatible afterloader [14]. However, the MRI-compatible 
afterloader is not clinically available yet.
Applicator design
The current most used applicator for HDREBT consists of eight catheters circumferentially placed 
near the edge of the applicator which allows selective use of channels for a more conformal treatment 
compared to one central channel. In addition, a shielding lead or tungsten insert can be placed in the 
central channel of the applicator to spare the contralateral healthy rectal wall. While EBRT techniques 
have evolved to become increasingly conformal using intensity modulated and dynamic arc radiotherapy, 
the applicator is limited in shielding options and is therefore far from conformal, which leaves substantial 
room for improvement. Several studies have proposed alternative applicator designs, aimed at increasing 
the conformality of the dose distribution. Webster et al. report on simulated dosimetric properties of 
several alternative applicator designs, mostly incorporating additional shielding [15]. In another paper, 
the same group describes dynamic modulated brachytherapy for rectal cancer [16]. The authors 
propose a design containing a long cylindrical tungsten alloy shield with a small window in which a 192Ir 
can be encapsulated, resulting in a highly directional beam profile. The shield should then be rotated and 
translated within the applicator by a robot arm in order to irradiate a target volume. So far, the dosimetric 
properties of these alternative applicator designs have only been produced using in silico simulations and 
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are not currently clinically used, possibly because of the complexity. Belezzo et al. describe an alternative 
applicator design that can be used for contact radiotherapy using a 192Ir source [17]. It contains multiple 
channels which allows planning optimization and tailoring of the dose distribution to the target volume. 
In addition, lateral shielding is incorporated, resulting in a uniform circular treatment surface with a 22 
mm diameter. This applicator could result in more conformal treatments of small tumors. However, the 
applicator is not clinically used yet.
Future use of HDREBT
Altough literature reports promising results on the use of HDREBT as a neoadjuvant treatment, no 
randomized trials have yet been performed comparing neoadjuvant HDREBT to neoadjuvant EBRT 
[18–20]. The currently ongoing CORRECT trial will show us whether the promising results presented so 
far can be reproduced in a randomized trial. In the CORRECT trial, patients with resectable rectal cancer 
are randomized between neoadjuvant chemoradiotherapy or neoadjuvant 4x 6.5 Gy HDREBT [21]. The 
primary endpoint is pathological complete response rate. However, time to surgery is not reported.
Given the increased interest in organ preservation, HDREBT may play a role in delivering a boost dose 
to the GTV to enhance the complete response rates. There has only been one randomized trial on the 
use of a HDREBT boost, in which patients were randomized between chemoradiation with or without 
a HDREBT boost of 2x 5 Gy, prescribed at 10 mm from the applicator surface [22]. No difference in 
pathological complete response was reported. However, the major response rate (defined as Mandard 
tumor regression grade 1 and 2) was significantly higher in the HDREBT group (44% vs 28%) for 
patients with a T3 tumor with no increase in toxicity. No effect on the major response rate was observed 
in T4 tumors [23]. An explanation could be that larger tumors that extend widely into the mesorectum 
are inaccessible to brachytherapy and/or the dose prescription at 10 mm from the applicator surface did 
not allow full coverage of the tumor.
The potential use of HDREBT in an organ preservation setting will depend on the ability to limit long-
term toxicity, since the rectum will not be removed. In the HERBERT trial, acute grade 2 and 3 proctitis 
was observed in 68.4% and 13.2% of patients respectively, while late grade 2 and grade ≥3 proctitis 
occurred in 48% and 40% of patients. The most severe toxicity was observed 12-18 months after 
treatment [24]. An analysis on the predictive factors for toxicity in this group of patients showed that 
brachytherapy CTV size and high doses at the mucosa of the CTV was correlated to endoscopic toxicity 
at the tumor site [25]. Due to the steep dose gradient and the aim to enclose the CTV with the 100% 
isodose, the dose at the mucosa can reach 400%. The dose to the contralateral wall was not correlated 
to endoscopic toxicity, which suggests that the dose was reduced sufficiently using the balloon that was 
placed between the applicator and the contralateral healthy rectal wall. The HERBERT trial was a dose 
escalation study, which partly explains the observed toxicity. In addition, no shielding was used and most 
patients in this study were treated with a single planning CT for all fractions, leading to uncertainties 
in the delivered dose to the CTV and surrounding healthy tissue. The added value of a HDREBT boost 
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after EBRT in elderly, frail patients will be further assessed in the HERBERT 2 trial. In this phase III trial, 
patients will be randomized between 13 x 3 Gy EBRT with or without a HDREBT boost of three weekly 
fractions of 7 Gy, at least 10 weeks after the end of EBRT. The primary endpoint is clinical complete 
response at 6 months after brachytherapy.
So far, the trials that have reported on the clinical outcome after HDREBT for rectal cancer vary in dose 
prescription methods, fractionation schemes, study endpoints and toxicity reporting [26,27]. In order to 
determine the added value of HDREBT in different clinical scenarios and to be able to compare different 
trials, consensus on the mentioned variables is urgently needed.
External beam radiotherapy
Higher doses to the tumor are suggested to result in higher complete response rates, which is interesting 
in the light of increased interest for organ preservation [28]. Due to the limited soft tissue contrast of 
imaging used for setup correction, such as CBCT, setup correction based on the GTV itself is not possible. 
Since fiducial markers are visible on (CB)CT imaging, they could be used as a surrogate for the GTV for 
setup correction in a GTV boost setting. Such an approach requires that the fiducials are representative 
of the GTV, and therefore stable with respect to the GTV. In addition, the spatial relationship between 
the fiducials and the GTV has to be determined, preferably on MRI, which means that they have to be 
visible on MRI. The visibility of fiducials on MRI as evaluated in Chapter 3 has already been discussed in 
the previous paragraph.
Stability of fiducials relative to the GTV and inter- and intrafraction displacement
In Chapter 5, we have determined the stability of fiducials relative to the GTV and the inter- and 
intrafraction displacement of fiducials relative to bony anatomy. Subsequently, we have derived 
required margins in different setup correction scenarios in a GTV boost setting. The use of setup 
correction based on fiducials results in a substantial margin reduction compared to setup correction 
based on bony anatomy. The findings of this study were based on imaging that was mostly acquired 
in the first week of radiotherapy. While that makes it applicable for a boost during or directly after a 
short course radiotherapy schedule, it may not apply for a boost applied during or after a long-course 
chemoradiotherapy schedule. In a recent study it has been shown that tumor regression during LC-CRT 
occurred mostly during the first half of treatment [29]. The displacement of the fiducials relative to the 
GTV and the inter- and intrafraction displacement relative to bony anatomy may be different at the end 
of a LC-CRT schedule, after most GTV regression has taken place.
Dose escalation to the GTV can be achieved by using a simultaneous integrated boost (SIB) or a 
sequential boost. Boosting using a SIB with setup correction based on fiducials would require daily plan 
re-optimization to take into account the GTV position of that day. Alternatively, the boost dose could 
be given after the elective dose of each fraction. This would require setup correction twice for each 
fraction: once based on bony anatomy for the elective irradiation of the CTV and once for the GTV boost. 
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A sequential GTV boost could be given after all fractions of the elective CTV irradiation have been given. 
Given the GTV shrinkage during the treatment, a sequential boost would be applied on a smaller residual 
GTV, thereby minimizing the additional dose to the organs at risk. In addition, it would allow for selection 
of patients that could possibly benefit from a GTV boost. 
A sub analysis in Chapter 5 suggests a difference in GTV displacement between tumors located in 
the lower rectum and tumors located in the mid- and upper rectum. As a result, the potential margin 
reduction by performing setup correction based on fiducials is smaller for low-lying tumors, compared 
to higher tumors. This raises the question whether the use of fiducials is justified for lower tumors. 
However, the difference in inter- and intra-fraction displacement between tumors located in the lower 
rectum and tumors located in the mid- or upper rectum should be verified in a larger patient cohort. 
Finally, the introduction and clinical implementation of MRI systems with integrated linear accelerators 
will obviate the need for fiducial markers. With such systems, the GTV can be imaged (real time) with the 
superior soft tissue contrast of MRI. However, MRI systems with integrated linear accelerators are not 
widely available yet. Until such systems are widely available, a GTV boost should be given using setup 
correction based on fiducials in order to reduce margins, and therefore dose to healthy tissue.
STAR-TReC planning study
In the STAR-TReC trial, a novel target volume is used which only includes the mesorectum. There is lack 
of data on the association of dose to bowel, bladder and femoral heads and the risk of late complications 
for dose levels up to 50 Gy. In addition, there is no data regarding OAR constraints using this novel target 
volume. Therefore, there were no mandated OAR constraints but optimization objectives were specified 
for the dose to the OAR for dose levels of 20-45 Gy. As a result, there was substantial variation in the 
dose to organs at risk between centers after treatment planning for 5 cases, while all cases fulfilled 
target volume constraints. Furthermore, we demonstrated that a study group meeting with subsequent 
replanning led to better treatment plans, with decreased dose to the organs at risk and decreased 
variability between centers.
These observations show the added value of performing QA for a clinical study. The question remains 
whether the study group meeting itself led to higher quality treatment plans, or that only the distribution 
of initial planning results among centers could potentially lead to the same result. By comparing initial 
planning results, centers were able to determine whether a treatment plan could be further optimized. 
This illustrates the inherent limitations of manual optimization of the treatment plan. Although the 
experience of the planner certainly influences the plan quality, determining whether a plan can be further 
optimized can be even difficult for experienced planners. Automated treatment planning techniques, 
such as knowledge-based treatment planning, protocol-based automatic iterative optimization or 
multicriteria optimization can aid in the decision whether a plan can be further optimized [30]. The 
added value of automated treatment planning is also observed in the differences in dose to organs at risk 
between cases. While in some cases the objectives might be easily reached, in other cases the objectives 
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might be hard to satisfy, depending on patient anatomy. This shows the limitation of imposing fixed 
constraints/objectives for treatment planning. Nonetheless, automated treatment planning can aid in 
the decision whether a plan can be further optimized, but will still lead to a broad range of acceptable 
plans if there is a lack of evidence on dose volume constraints. Therefore, automated treatment planning 
is not expected to lead to a substantial decrease in variability. The lack of evidence also contributes to 
the observed variability in dose to the organs at risk. In order to develop dose volume constraints and 
optimization objectives for an organ preservation setting, toxicity and clinical outcome data has to be 
carefully collected.
The treatment plan quality achieved in Chapter 6 may be higher compared to treatment plans produced 
in clinical practice, as in clinical practice less extensive discussion and time is spent on the treatment 
plan. In order to monitor treatment plan quality in a clinical trial, it can be beneficial to require regular QA 
of treatment plans. As an educational process, a similar QA as presented in Chapter 6 can be performed, 
identifying differences between centers and followed by a discussion how to handle them.
114 | Chapter 7
REFERENCES
1. Peters FP, Teo MTW, Appelt AL, Bach S, Baatrup G, de Wilt JHW, et al. Mesorectal radiotherapy for early stage rectal 
cancer: a novel target volume. Clin Transl Radiat Oncol 2020.
2. Vuong T, Devic S, Moftah B, Evans M, Podgorsak EB. High-dose-rate endorectal brachytherapy in the treatment of 
locally advanced rectal carcinoma: Technical aspects. Brachytherapy 2005;4:230–5.
3. Devic S, Vuong T, Moftah B, Evans M, Podgorsak EB, Poon E, et al. Image-guided high dose rate endorectal 
brachytherapy. Med Phys 2007;34:4451–8.
4. Vuong T, Devic S. High-dose-rate pre-operative endorectal brachytherapy for patients with rectal cancer. J Contemp 
Brachytherapy 2015;7:181–6.
5. Nout RA, Bekerat H, Devic S, Vuong T. Is Daily CT-Based Adaptive Endorectal Brachytherapy of Benefit Compared 
to Using a Single Treatment Plan for Preoperative Treatment of Locally Advanced Rectal Cancer? Brachytherapy 
2016;15:S83–4.
6. Rigter LS, Rijkmans EC, Inderson A, van den Ende RPJ, Kerkhof EM, Ketelaars M, et al. EUS-guided fiducial marker 
placement for radiotherapy in rectal cancer: feasibility of two placement strategies and four fiducial types. Endosc Int 
Open 2019;07:E1357–64.
7. Gurney-Champion OJ, Lens E, Van Der Horst A, Houweling AC, Klaassen R, Van Hooft JE, et al. Visibility and 
artifacts of gold fiducial markers used for image guided radiation therapy of pancreatic cancer on MRI. Med Phys 
2015;42:2638–47.
8. Maspero M, Van Den Berg CAT, Zijlstra F, Sikkes GG, De Boer HCJ, Meijer GJ, et al. Evaluation of an  
automatic MR-based gold fiducial marker localisation method for MR-only prostate radiotherapy. Phys Med Biol 
2017;62:7981–8002.
9. Ghose S, Mitra J, Rivest-Hénault D, Fazlollahi A, Stanwell P, Pichler P, et al. MRI-alone radiation therapy planning for 
prostate cancer: Automatic fiducial marker detection. Med Phys 2016;43:2218–28.
10. Dinis Fernandes C, Dinh C V., Steggerda MJ, ter Beek LC, Smolic M, van Buuren LD, et al. Prostate fiducial marker 
detection with the use of multi-parametric magnetic resonance imaging. Phys Imaging Radiat Oncol 2017;1:14–20.
11. De Roover R, Crijns W, Poels K, Peeters R, Draulans C, Haustermans K, et al. Characterization of a novel liquid  
fiducial marker for multimodal image guidance in stereotactic body radiotherapy of prostate cancer. Med Phys 
2018;45:2205–17.
12. Riisgaard de Blanck S, Scherman Rydhög J, Richter Larsen K, Frost Clementsen P, Josipovic M, Camille Aznar M, et al. 
Safety and long-term visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell 
lung cancer. Clin Transl Radiat Oncol 2018;13:24–8.
13. ClinicalTrials.gov; registration no. NCT03265418. Accessed December 2, 2019
14. Beld E, Seevinck PR, Schuurman J, Viergever MA, Lagendijk JJW, Moerland MA. Development and Testing of a 
Magnetic Resonance (MR) Conditional Afterloader for Source Tracking in Magnetic Resonance Imaging-Guided  
High-Dose-Rate (HDR) Brachytherapy. Int J Radiat Oncol 2018;102:960–8.
15. Gwynne S, Mukherjee S, Webster R, Spezi E, Staffurth J, Coles B, et al. Imaging for target volume delineation in rectal 
cancer radiotherapy - a systematic review. Clin Oncol 2012;24:52–63.
16. Webster MJ, Devic S, Vuong T, Yup Han D, Park JC, Scanderbeg D, et al. Dynamic modulated brachytherapy (DMBT) 
for rectal cancer. Med Phys 2013;40.
17. Bellezzo M, Fonseca GP, Verrijssen AS, Voncken R, Van den Bosch MR, Yoriyaz H, et al. A novel rectal applicator for 
contact radiotherapy with HDR 192 Ir sources. Brachytherapy 2018;17:1037–44.
General discussion | 115
18. Vuong T, Richard C, Niazi T, Liberman S, Letellier F, Morin N, et al. High dose rate endorectal brachytherapy for 
patients with curable rectal cancer. Semin Colon Rectal Surg 2010;21:115–9.
19. Garfinkle R, Lachance S, Vuong T, Mikhail A, Pelsser V, Gologan A, et al. Is the pathologic response of T3 rectal 
cancer to high-dose-rate endorectal brachytherapy comparable to external beam radiotherapy? Dis Colon Rectum 
2019;62:294–301.
20. Hesselager C, Vuong T, Påhlman L, Richard C, Liberman S, Letellier F, et al. Short-term outcome after neoadjuvant 
high-dose-rate endorectal brachytherapy or short-course external beam radiotherapy in resectable rectal cancer. 
Color Dis 2013;15:662–6.
21. ClinicalTrials.gov; registration no. NCT02017704. Accessed December 1, 2019
22. Jakobsen A, Ploen J, Vuong T, Appelt A, Lindebjerg J, Rafaelsen SR. Dose-effect relationship in chemoradiotherapy 
for locally advanced rectal cancer: A randomized trial comparing two radiation doses. Int J Radiat Oncol Biol Phys 
2012;84:949–54.
23. Appelt AL, Vogelius IR, Pløen J, Rafaelsen SR, Lindebjerg J, Havelund BM, et al. Long-term results of a randomized 
trial in locally advanced rectal cancer: No benefit from adding a brachytherapy boost. Int J Radiat Oncol Biol Phys 
2014;90:110–8.
24. Rijkmans EC, van Triest B, Nout RA, Kerkhof EM, Buijsen J, Rozema T, et al. Evaluation of clinical and endoscopic 
toxicity after external beam radiotherapy and endorectal brachytherapy in elderly patients with rectal cancer treated 
in the HERBERT study. Radiother Oncol 2018;126:417–23.
25. Rijkmans EC, Marijnen CAM, van Triest B, Ketelaars M, Cats A, Inderson A, et al. Predictive factors for response and 
toxicity after brachytherapy for rectal cancer; results from the HERBERT study. Radiother Oncol 2019;133:176–82.
26. Buckley H, Wilson C, Ajithkumar T. High-Dose-Rate Brachytherapy in the Management of Operable Rectal Cancer:  
A Systematic Review. Int J Radiat Oncol Biol Phys 2017;99:111–27.
27. Verrijssen AS, Opbroek T, Bellezzo M, Fonseca GP, Verhaegen F, Gerard JP, et al. A systematic review comparing 
radiation toxicity after various endorectal techniques. Brachytherapy 2018;18:71-86.e5.
28. Appelt AL, Ploen J, Vogelius IR, Bentzen SM, Jakobsen A. Radiation dose-response model for locally advanced rectal 
cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys 2013;85:74–80.
29. Van den Begin R, Kleijnen J-P, Engels B, Philippens M, van Asselen B, Raaymakers B, et al. Tumor volume regression 
during preoperative chemoradiotherapy for rectal cancer: a prospective observational study with weekly MRI. Acta 
Oncol (Madr) 2017;0:1–5.
30. Hussein M, Heijmen BJM, Verellen D, Nisbet A. Automation in intensity modulated radiotherapy treatment planning— 
a review of recent innovations. Br J Radiol 2018;91:20180270.
116 | Chapter 7
General discussion | 117
Chapter 8
Summary
118 | Chapter 8
SUMMARY
Improvements in the treatment of rectal cancer patients have led to increased survival. As a result, long-
term outcome has become an increasingly important factor. In addition, the introduction of population 
screening will lead to earlier detection of the disease with probably improved survival as a result. Both 
preoperative (chemo)radiotherapy and TME surgery are associated with toxicity and complications. As 
a result, research for rectal cancer treatment has focused on the reduction of radiation dose to (healthy) 
tissue and less extensive surgery or omission of surgery in selected patients. The work described in this 
thesis can be used to decrease the uncertainties related to image-guided external beam radiotherapy 
and high-dose-rate endorectal brachytherapy (HDREBT) of rectal cancer.
HDREBT can be used to deliver high doses to the tumor while sparing surrounding organs at risk due 
to a steep dose gradient. Most publications on the use of HDREBT focus on oncological outcomes, 
but do not report on the technical aspects of the procedure. Chapter 2, 3 and 4 of this thesis focus 
on improvements of the HDREBT treatment planning procedure in terms of required imaging and the 
transition to MRI-only treatment planning.
Chapter 2 compares the use of a single planning CT for all subsequent fractions and the use of a planning 
CT at each fraction (repeat CT) in terms of target volume coverage and dose to organs risk. In 8/22 
fractions, a CTV D98 of at least 85% could not be achieved due to incorrect applicator balloon setup or 
remaining air and/or feces between the CTV and the applicator and an intervention would be necessary. 
Therefore, repeat CT imaging should be the minimal standard practice to check for a correct applicator 
setup. In addition, replanning based on repeat CT imaging resulted in more conformal treatment plans 
and is therefore recommended.
To be able to use MRI for treatment planning for HDREBT, MRI-compatible fiducial markers were needed 
as an alternative to endoluminal clips. In Chapter 3, the MRI visibility of four different gold fiducial 
markers is evaluated. Four observers identified fiducial locations on two MRI exams per patient in two 
scenarios: without and with corresponding (CB)CT available to provide an estimate of fiducial location 
on MRI. Fiducial identification was poor without a corresponding (CB)CT. With corresponding (CB)CT, 
the Visicoil 0.75 and the Gold Anchor were the most consistently identified fiducials and were best 
visible on T1 3D GRE images.
To enable MRI-only planning for HDREBT, the applicator and the individual channels need to be visible 
on MRI. However, the applicator creates a signal void on currently used anatomical MRI images. Chapter 
4 shows that an ultrashort-echo time (UTE) MRI sequence can be used to visualize the applicator 
and the individual channels for HDREBT treatment planning. On the UTE images, there was sufficient 
contrast to discern the individual channels within the applicator, both in a phantom and in patients. After 
rigid registration to a 3D T
1
-weighted sequence, the residual 95th percentile of the geometric distortion 
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inside a 550 mm diameter sphere was 0.8 mm (LR), 1.0 mm (AP) and 0.9 mm (CC) mm, which is within 
acceptable range.
Complete response rates might be increased by delivering a higher dose to the tumor, which is beneficial 
in organ preservation strategies. Although extensive research has been performed on the inter- and 
intrafraction displacement of the CTV relative to the bony anatomy, limited research was performed on 
the inter- and intrafraction displacement of the GTV relative to bony anatomy to determine margins for 
an external beam radiotherapy GTV boost. As a result, a wide range of clinically used PTV margins of 7-30 
mm is described in literature. Setup correction could potentially be performed based on the fiducials 
instead of bony anatomy. To do so, the fiducials need to be representative of the GTV and the fiducials 
should be visible on MRI to accurately determine the fiducial-GTV spatial relationship. In Chapter 5, 
the stability of fiducials relative to the GTV and the inter- and intrafraction displacement of fiducials 
relative to bony anatomy is determined. A fiducial displacement of around 3 mm (LR and AP) and 4 mm 
(CC) relative to the GTV was observed. In addition, large interfraction displacements of the GTV
 
and the 
fiducials relative to bony anatomy were found. Therefore, despite the observed fiducial displacement 
relative to the GTV, the use of fiducials as a surrogate for GTV position reduces the required margins 
from 20 mm to 8 mm in the AP direction and from 20 mm to 13 mm in the CC direction. A sub analysis 
shows that this reduction in margin may be larger in patients with tumors located in the mid- and upper 
rectum compared to the lower rectum.
In order to facilitate organ preservation in early stage rectal cancer patients, (chemo)radiotherapy has 
to be given in order to control the tumor. It is doubtful whether the typically used large target volume 
is required for these patients and reduction of the target volume to only include the peritumoral region 
of the primary tumor and mesorectum seems reasonable. The significant volume reduction might lead 
to decreased treatment-related toxicity without compromising oncological outcome. This is currently 
being investigated in the STAR-TReC trial, which assesses the feasibility of short-course radiotherapy 
or long-course chemoradiotherapy with subsequent two-stage response assessment as an alternative 
to TME surgery. The radiotherapy target volume only includes the mesorectum. Chapter 6 determines 
the treatment plan variability in terms of dose to OAR and assesses the effect of a national study group 
meeting on the quality and variability of treatment plans for mesorectum-only treatment planning. 
Eight centers produced treatment plans for five cases and a study group meeting for the participating 
centers was organized to discuss the planning results. At the meeting, the values of the treatment plan 
DVH parameters were distributed among centers so that results could be compared. Subsequently, the 
centers were invited to perform replanning if they considered this to be necessary. Dose to OAR varied 
considerably between centers, especially for dose levels below 20 Gy. The study group meeting and the 
distribution of the initial planning results among centers resulted in lower dose to the defined OAR and 
reduced variability between centers after replanning.





Verbeteringen van de behandeling voor patiënten met endeldarmkanker hebben geresulteerd in 
een verbeterde overleving. Daarnaast vindt door het bevolkingsonderzoek vroegere opsporing van 
endeldarmkanker plaats en hierdoor zal de overleving waarschijnlijk verder verbeteren. Door de 
(verwachte) verbeterde overleving worden de lange-termijn effecten van de behandeling steeds 
belangrijker. Preoperatieve (chemo)radiotherapie en totale mesorectale excisie (TME) chirurgie 
zijn geassocieerd met toxiciteit en chirurgische complicaties. Onderzoek naar de behandeling van 
endeldarmkanker is daarom gericht op het verlagen van de radiotherapie dosis op gezond weefsel en 
minder uitgebreide chirurgie of het achterwege laten van chirurgie in geselecteerde patiënten. Een 
radiotherapie behandeling van de endeldarm kan zowel via uitwendige als inwendige bestraling gegeven 
worden. Beide bestralingstechnieken hebben bepaalde behandelonderzekerheden, zoals het bepalen 
van de tumor op de beschikbare beeldvorming en de positionering van de patiënt op de bestralingstafel. 
Door deze behandelonzekerheden wordt er een veiligheidsmarge rondom het te bestralen doelvolume 
gebruikt om ervoor te zorgen dat de tumor daadwerkelijk de voorgeschreven dosis ontvangt. Het nadeel 
hiervan is dat naastgelegen gezond weefsel meer stralingsdosis ontvangt en een extra dosis op de 
tumor daardoor beperkt mogelijk is. De resultaten die zijn beschreven in dit proefschrift kunnen worden 
gebruikt om de behandelonzekerheden voor zowel uitwendige als inwendige bestraling van patiënten 
met endeldarmkanker te verlagen.
Inwendige bestraling met behulp van een applicator, ook wel brachytherapie, kan vanwege zijn steile dosis 
gradiënt gebruikt worden om een hoge stralingsdosis te geven aan de tumor terwijl omliggende organen 
gespaard worden. De meeste publicaties over het gebruik van brachytherapie bij endeldarmkanker 
richten zich op oncologische uitkomsten, maar rapporteren niet over de technische aspecten van de 
procedure. Hoofdstuk 2, 3 en 4 richten zich op verbeteringen van de brachytherapie planningsprocedure 
bij endeldarmkanker voor wat betreft benodigde beeldvorming en de stap naar een planningsprocedure 
die uitsluitend gebaseerd is op MRI beeldvorming.
Hoofdstuk 2 vergelijkt het gebruik van een enkel CT onderzoek voor het plannen van alle bestralingsfracties 
met het gebruik van een CT onderzoek bij elke bestralingsfractie (herhaal CT), waarbij er gekeken wordt 
naar de dekking van het doelvolume en de dosis op de gezonde weefsels. Bij 8 van de 22 fracties kon 
een dekking van het doelvolume van minstens 85% niet behaald worden door een incorrecte plaatsing 
van de applicator ballon of resterende lucht en/of ontlasting tussen het doelvolume en de applicator. Bij 
deze 8 fracties zou een interventie nodig zijn om de positionering van de applicator te corrigeren. Het 
gebruik van een planning CT scan bij elke fractie zou daarom de minimale standaard moeten zijn om de 
positionering van de applicator te controleren. Ten slotte resulteerde herplannen op basis van de herhaal 
CT in meer conforme bestralingsplannen.
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Om MRI te kunnen gebruiken bij het maken van het bestralingsplan zijn MRI-compatibele markers nodig 
als alternatief voor de huidige chirurgische clips om de tumor te markeren. In Hoofdstuk 3 wordt de MRI 
zichtbaarheid van vier verschillende goudmarkers beoordeeld. Vier waarnemers hebben markerposities 
aangeduid op twee MRI onderzoeken per patiënt in twee scenario’s: met en zonder de beschikbaarheid 
van een bijbehorend CT onderzoek om een schatting te geven van de markerposities op MRI. Het 
aanduiden van goudmarkers zonder bijbehorend CT onderzoek resulteerde in veel verschillen tussen de 
waarnemers. Met het gebruik van het bijbehorende CT onderzoek waren de Visicoil 0.75 en Gold Anchor 
de meest consistent aangeduide markers en deze waren het best zichtbaar op de T1 gewogen 3D GRE 
MRI beelden.
Om voor brachytherapie een bestralingsplan te kunnen maken dat uitsluitend gebaseerd is op MRI 
beeldvorming moeten de applicator en de individuele kanalen in de applicator zichtbaar zijn op de MRI 
beeldvorming. Echter, op de huidige gebruikte anatomische MRI beeldvorming is de applicator afgebeeld 
als een zwarte vlek door gebrek aan signaal. Hoofdstuk 4 toont aan dat een MRI onderzoek met een 
ultrakorte echotijd gebruikt kan worden om de applicator en de individuele kanalen af te beelden. 
Dit MRI beeld geeft voldoende onderscheid tussen de individuele kanalen, zowel op beelden van een 
fantoom als beelden van patiënten met een applicator in de endeldarm. Na de fusie met een T1 gewogen 
3D MRI onderzoek is de resterende geometrische verstoring binnen een bol met een diameter van 550 
mm voor alle richtingen ongeveer 1 mm, wat een klinisch acceptabele afwijking is.
Het percentage patiënten waarbij de tumor volledig verdwenen is na (chemo)radiotherapie zou 
verhoogd kunnen worden door een hogere stralingsdosis te geven aan de tumor. Dit kan interessant zijn 
voor orgaansparende behandelingen, waarbij bij geselecteerde patiënten chirurgie achterwege wordt 
gelaten of minder uitgebreide chirurgie toegepast wordt. Er is uitgebreid onderzoek verricht naar de 
beweging van de gehele endeldarm ten opzichte van de botten, maar er is slechts beperkt onderzoek 
verricht naar de beweging van de tumor ten opzichte van de botten om veiligheidsmarges te bepalen 
voor een extra dosis op de tumor met uitwendige radiotherapie. Om die reden worden er in de literatuur 
uiteenlopende veiligheidsmarges van 7-30 mm beschreven. Positieverificatie voor een extra dosis op 
de tumor zou gebaseerd kunnen worden op geïmplanteerde markers in plaats van op botten. Om dit te 
realiseren moeten de markers representatief zijn voor de positie van de tumor en zichtbaar zijn op MRI 
om de markerposities ten opzichte van de tumor nauwkeurig te kunnen bepalen. In Hoofdstuk 5 wordt 
de stabiliteit van de markers ten opzichte van de tumor en de beweging van de markers ten opzichte 
van de botten bepaald. Tussen bestralingsfracties werd een markerverplaatsing van 3 tot 4 mm ten 
opzichte van de tumor gevonden. Daarnaast werden er grote verplaatsingen van de tumor en de markers 
gevonden ten opzichte van de botten. Om die reden leidt het gebruik van markers als surrogaat voor de 
tumor tot een afname van de veiligheidsmarge van 20 mm naar 13 mm tot zelfs 8 mm, afhankelijk van de 
richting in de patiënt. Een subanalyse suggereert dat deze veiligheidsmarge meer afneemt bij patiënten 
met een tumor in het centrale en hooggelegen deel van de endeldarm vergeleken met patiënten met een 
tumor in het laaggelegen deel van de endeldarm.
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Om patiënten met een vroeg stadium endeldarmkanker orgaansparend te kunnen behandelen, zullen 
deze patiënten (chemo)radiotherapie moeten krijgen om de tumor te bestrijden. Het is waarschijnlijk 
niet nodig om bij deze patiënten de reguliere grote doelvolumes te gebruiken, dus het beperken van het 
doelvolume tot enkel het gebied van de primaire tumor en het mesorectum lijkt redelijk. De flinke afname 
van het doelvolume zou kunnen leiden tot verminderde toxiciteit zonder verslechterde oncologische 
uitkomst. Dit wordt op dit moment onderzocht in de STAR-TReC studie, waarin de haalbaarheid van 
korte serie radiotherapie of lange serie chemoradiotherapie gevolgd door twee respons evaluaties 
als alternatief op TME chirurgie geëvalueerd wordt. In Hoofdstuk 6 wordt voor bestralingsplannen 
met een doelvolume dat alleen bestaat uit het mesorectum de variabiliteit van dosis op de gezonde 
weefsels bepaald. Daarnaast wordt het effect van een nationale bijeenkomst op de kwaliteit en de 
variabiliteit van bestralingsplannen geëvalueerd. Acht radiotherapie afdelingen hebben ieder voor vijf 
patiënten bestralingsplannen gemaakt en vervolgens werd er een bijeenkomst georganiseerd voor de 
deelnemende radiotherapie afdelingen om de planningsresultaten te bespreken. Bij de bijeenkomst 
werden de dosisgegevens van de bestralingsplannen met elkaar gedeeld, zodat deze met elkaar konden 
worden vergeleken. Na de bijeenkomst werden de deelnemende afdelingen verzocht om voor iedere 
patiënt te bepalen of zij het bestralingsplan zouden willen herzien. De dosis op de gezonde weefsels 
was substantieel verschillend tussen de deelnemende afdelingen, in het bijzonder voor de lage dosis 
niveaus onder de 20 Gy. De bijeenkomst en het delen van de oorspronkelijke planningsresultaten onder 
de deelnemende afdelingen resulteerde in een lagere dosis op de gezonde weefsels en een lagere 
variabiliteit tussen de deelnemende afdelingen na het herzien van de bestralingsplannen.
De bevindingen beschreven in dit proefschrift kunnen worden gebruikt om de behandelonzekerheden 
voor zowel de uitwendige als inwendige bestraling van patiënten met endeldarmkanker te verlagen. 
Door het verlagen van de behandelonzekerheden kan het doelvolume meer conform worden bestraald 
waardoor er minder stralingsdosis op naastgelegen gezond weefsel komt en er een hogere extra dosis op 
de tumor mogelijk wordt.
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